Date: 20100120
Docket: T-880-03
Citation: 2010 FC 63
Toronto,
Ontario, January 20, 2010
PRESENT: The Honourable Mr. Justice Campbell
BETWEEN:
TRUEHOPE NUTRITIONAL SUPPORT LIMITED
AND DAVID HARDY
Applicants
and
THE ATTORNEY GENERAL OF CANADA AND
THE MINISTER OF HEALTH
Respondents
REASONS FOR ORDER AND ORDER
[1]
In
the present Application, the Applicants challenge the constitutionality of the
seizure provisions of the Food and Drug Act, R.S., 1985, c. F-27 (FDA)
as offending Section 7 and Section 8 Charter rights.
[2]
The
Applicant, Mr. David Hardy, is a co-founder and the operating mind of the
corporate Applicant TrueHope Nutritional Support Limited (TrueHope). TrueHope manages
the production, sale of, and consumer support for a natural health product
called EMpowerplus which is promoted
as a treatment for mental illness. The
conduct which grounds the constitutional challenge is the seizure of two
shipments of EMpowerplus by officials of Health Canada which, under
the auspices of the Minister of Health, is the Federal Department responsible
for helping Canadians maintain and improve their health.
[3]
Section
23 of the FDA allows a Health Canada inspector to seize articles which
he or she believes, on reasonable grounds, contravene the FDA and its
regulations at any given point in time (the FDA Regulations). Section 26
of the FDA allows the detention of articles seized until the inspector who
executed the seizure is satisfied that they comply with the FDA and the FDA
Regulations. The seizures of EMpowerplus under review occurred in April and
May, 2003, and the product in the April shipment seized has remained in
detention since that time.
[4]
The
seizures are the seminal event in a history of conflict between Mr. Hardy and
Health Canada over the
sale in Canada of EMpowerplus. In April 2001, Health Canada served notice that
TrueHope’s conduct of offering the product for sale in Canada is unlawful,
and Truehope’s refusal to cease the practice resulted in the seizures. At the
time of the seizures, hundreds if not thousands of people were dependent on
EMpowerplus as a treatment for their poor mental health. Because the seizures
were perceived by these users to be a direct threat to secure access of the
product, an immediate intensive public informational campaign was launched
against Health Canada’s enforcement action. The campaign proved to be
effective; within a year of the seizures an agreement was reached between TrueHope
and Health Canada with respect
to the conditions of sale
of EMpowerplus and which resulted in the
same access by users to the product that existed prior to the seizures.
[5]
Nevertheless,
the present Application which was launched immediately after the seizures has
been pursued to hearing. The critical relief sought are two declarations: the
Section 7 and 8 Charter rights of Truehope and Mr. Hardy are infringed
by the seizures; and s. 23(1)(d) and s. 26 of the FDA infringe Sections
7 and 8 of the Charter and are, therefore, of no force and effect. The
constitutional challenge to the seizure provisions of the FDA is advanced
in an effort to reduce the restricted access to health products imposed by the FDA
and the FDA Regulations. While the present Application does not
challenge the statutory and regulatory control measures directly, the objective
is to reduce their effectiveness by fundamentally altering the provisions used
for their enforcement.
[6]
The
Applicants argue that the seizure provisions of the FDA offend Sections
7 and 8 of the Charter because the provisions do not provide, before a
seizure takes place, statutory access to argue the health risks that will be
caused by the seizure. The necessary change to the FDA regime is argued
to be the introduction of a form of procedural fairness that will provide a
measure of judicial control over the enforcement of the FDA and the FDA
Regulations.
[7]
Mr.
Hardy is not a user of EMpowerplus for a treatment purpose; his purely personal
Charter challenge is based in his Section 7 right to security being his
right to be free from the
psychological stress he suffered as a
result of the seizures. Thus, to achieve success in introducing
procedural fairness into the seizure
process under the FDA it is necessary for the Section 7 rights to life,
liberty, and security of users of EMpowerplus for a therapeutic purpose to be
brought into play. To achieve this result, Counsel for the Applicants argues
that Mr. Hardy’s personal Charter standing in the present Application opens
an opportunity to argue that the presently deficient enforcement provisions
breach the Charter rights of non-Applicant users of EMpowerplus and,
thus, they are unconstitutional.
[8]
For
success, Mr. Hardy’s personal Charter claim depends on the quality of
the evidence on the record, and the argument that Charter claims of
non-Applicant users can be considered depends on a correct interpretation of
the law with respect to standing to bring a Charter challenge. For the
reasons which follow, I find that the Application fails on both grounds.
[9]
At
the outset, a preliminary matter requires attention. In the course of oral
argument, Counsel for the Respondents argued that a question exists as to
whether, because of events which have transpired since the seizures took place,
the present Application is moot. However, given that Health Canada concedes that
because the product seized in 2003 is still in detention and a live controversy
still exists as to whether it should remain in detention, I find that the
Application is not moot on any ground.
I. The
Factual History Leading to the Present Application
[10]
For
clarification, in the narrative of these reasons the spelling of EMpowerplus
and TrueHope is that used by Mr. Hardy in his affidavit. The spelling and
format used by other participants are variable in the documents referred to in
these reasons.
[11]
The
history of the development and marketing of EMpowerplus, and Health Canada’s
involvement in restricting access to the product, is not contested. However,
because the history provides the basis of Mr. Hardy’s Charter challenge,
the major events in his relationship with Health Canada are
necessary to state to support the reasons for the final determination of the
present Application.
A. The
development of EMpowerplus
[12]
As
an animal
nutritionist, Mr. Hardy discovered that feeding certain nutrients to pigs
helped alleviate their ear and tail biting syndrome. Mr. Hardy observed that
certain behaviors in humans such as hyper-irritability as well as symptoms
related to bipolar disorder are similar to what he observed in pigs and
speculated that if people were given certain nutrients, their symptoms could
also be alleviated.
[13]
In
1995, Mr. Anthony
Stephan, also a co-founder of TrueHope, sought Mr. Hardy’s advice about
treating the poor mental health of his children: his daughter Autumn was delusional
and suicidal, and his son, Joseph suffered from bursts of uncontrollable rage.
Given Mr. Hardy’s positive experience with treating similar conduct in pigs as
a nutrient deficiency, they placed
Autumn and Joseph on a course of off-the-
retail-shelf nutrients. The mental health of both improved.
[14]
In
1996, the positive experience with using nutrients to help people deal with
their mental problems led Mr. Hardy and Mr. Stephan to develop the Quad
Program, a treatment protocol of supplement vitamins and mineral nutrients. In
1996, Mr. Hardy and Mr. Stephan incorporated the Synergy Group of Canada Inc.
(Synergy) to promote research into the Quad Program and observe its results. A
Quad Program study at the University of Lethbridge and the University of Calgary revealed that due to inconsistency in the
mineral supplements, people on the protocol faltered. Mr. Hardy and Mr.
Stephan sought to improve the Quad Program and did so by developing a single
and consistent product, being EMpowerplus.
[15]
In
1998, Mr. Hardy’s son and daughter started on the Quad program: for his son
Landon, it was to treat his schizophrenia and psychotic episodes; and for his
daughter, Cherilea, it was to treat postpartum psychosis after having her first
child. Both benefited and continue to use EMpowerplus for a therapeutic
purpose.
[16]
In
1999, Mr. Hardy and Mr. Stephan founded TrueHope as a program to support users
of EMpowerplus. An essential feature of the program is that EMpowerplus is only
sold to persons who agree to enroll in the TrueHope program and the product is
only made available for sale to users enrolled in the program.
[17]
The
rationale for the management structure developed is that EMpowerplus requires
users to reduce or eliminate entirely their intake of psychiatric medication on
the belief that the transition from psychiatric medication to EMpowerplus
causes symptoms of mental disorders to return temporarily. Because of safety
concerns arising from the transition, TrueHope addresses these concerns by
helping new users adapt to EMpowerplus through counselling and nutrient
management. TrueHope also provides continued support through trained staff to
help manage participants and trains psychiatrists and physicians to help their patients
adapt to EMpowerplus.
[18]
Early
development of EMpowerplus took place in the United States in cooperation with
American partners. In late 2002, TrueHope moved its support program to Raymond
Alberta,
and TrueHope’s corporate partner Synergy started to be used as a revenue bearing
company to manage sales of EMpowerplus. At all times material to the seizures
under review, warehousing, and distribution occurred in the United Stated
through the Utah firm Pharos DTB LL (Pharos) and manufacturing took
place in the United
States.
However, it is uncontested that EMpowerplus was sold to users in Canada by Synergy
through offering the product for sale on the TrueHope website as a treatment
for mental disorders.
[19]
At
the time of the seizures, the selling practice was as follows: Synergy took
orders through a toll-free number advertised on TrueHope’s website; the orders
were relayed to and filled by Pharos; Pharos shipped the orders to Synergy in
Canada through United Parcel Service (UPS) as a customs agent; to save shipping
costs, many orders were shipped together as a single shipment but
each shipment contained separately-invoiced
packages each addressed to TrueHope users; and once in Canada each package
was delivered to each user by UPS.
[20]
The
fact that TrueHope offered EMpowerplus for sale in Canada for the treatment of
mental disorders proved to be highly contentious to Health Canada.
B. Health Canada’s
enforcement action and TrueHope’s response
[21]
It is not contested that,
in 2003, Truehope was offering EMpowerplus for sale in Canada through its website
without the required Health Canada authorization. It is also not contested that the seizures
under review were conducted as a direct result of TrueHope’s failure to comply
with Health Canada’s demand,
first made in 2001, that it cease its unauthorized conduct. Therefore, apart
from the Charter challenge aspect of the present Application, there is
no question that Health Canada had sound legal reasons to perform the seizures
for breaches of the FDA and the FDA Regulations as they existed
in 2003.
[22]
Because
the reasons for the seizures are not contested, it is unnecessary to elaborate
on the various provisions of the FDA and FDA Regulations that
ground the seizures. Indeed, these provisions are clearly summarised in Health Canada’s April 27,
2001 warning letter from Health Canada Inspector Mr. Miles E. Brosseau to Synergy that it was
operating in violation of the law:
Mr. Anthony Stephan
Synergy Group of Canada, Inc.
635 – 2nd Avenue West
Cardston, Alberta T0K 0K0
Attention: Mr. Stephan
RE: WARNING: Violation
of Sections 3(1), 3(2), 9(1), 9(2), C.01.003, C.01.005, C.01.004.1,
C.01.014(1), C.01A.004.(1), C.08.002, and C.08.005 of the FOOD AND DRUGS ACT
AND REGULATIONS.
-----------------------------------------------------------------------------------
It is apparent that the Synergy Group
of Canada Inc. is advertising and selling the unapproved drug
product, “E.M.Power”, through your website at www.truehope.com.
The website solicits participation in a clinical
trial research and seeks to attract parents of children with mental illness
with statements such as “finding true hope in despair”. The product is
being promoted for the study and treatment of serious disorders such as anxiety
and panic disorder, bipolar affective disorder, fibromyalgia, schizophrenia,
attention deficit hyperactive disorder, clinical depression, Tourett’s Syndrome,
etc. which are not amenable to self diagnosis or self-monitoring.
The activities of the Synergy Group of
Canada Inc. are considered violative of the above noted sections and compliance
with the regulatory requirements is necessary.
The sale and advertisement of a drug, and
in this case a new drug, prior to receipt of a Notice of Compliance (NOC)
and a Drug Identification number (DIN) is in violation of sections
C.01.014(1), and C.08.002.
E.M.Power has not received a DIN or NOC for any of the indications for which it
is being sold and advertised and is not properly labelled. Consequently, the
false, misleading, and deceptive selling/advertising of this unapproved and improperly
labelled drug product is in violation of sections 9(1), 9(2), C.01.003,
C.01.004.01, and C.01.005.
As well, marketing E.M.Power for diseases
that are listed in Schedule A is a violation of sections 3(1) and 3(2).
As per section C.01A.04(1), no person
shall distribute a drug product in Canada without an establishment licence.
You were previously advised [by letter
dated October 20, 2000] that the Food and Drugs Act and Regulations require
that an Investigational New Drug Submission (IND) be filed for
evaluation prior to initiating a clinical
trial. A “No
Objection Letter” would be issued, should review of the proposed clinical
trial be considered satisfactory. Failure to submit an IND with respect to the research conducted with E.M. Power is
in violation to section C.08.005.
A copy of definitions, Schedule A, and
the violated sections is attached for your reference. It is my recommendation
that you disseminate this information to the parties involved (ie. Corporate
directors, clinical trial investigators, the manufacturer, and Synergy research
assistants).
It is imperative that the sale,
distribution, any form of advertising, and research with the product E.M.Power
be concluded immediately. I am requesting, by May 31, 2001, your written
response confirming that the violative activities have ceased and that the
Synergy Group of Canada Inc. will maintain compliance with the Food and Drugs
Act and Regulations.
If you have further questions or wish
discussion please call […]
[Emphasis in the original]
(Respondents’ Record, Vol. 2, p. 382)
[23]
The
key provisions of the FDA mentioned in the April 27, 2001 letter are as
follows:
Foods, drugs, cosmetics and
devices
|
Aliments, drogues, cosmétiques
et instruments
|
3. (1)
No person shall advertise any food, drug, cosmetic or device to the general
public
as
a treatment, preventative or cure for any of the diseases, disorders or
abnormal physical
states
referred to in Schedule A.
(2)
No person shall sell any food, drug, cosmetic or device
(a)
that is represented by label, or
(b)
that the person advertises to the general Public as a treatment, preventative
or cure for any of the diseases, disorders or abnormal physical
states
referred to in Schedule A.
|
3. (1) Il est interdit de faire, auprès du
grand
public, la publicité d’un aliment,
d’une drogue,
d’un cosmétique ou d’un instrument à
titre de
traitement ou de mesure préventive
d’une maladie,
d’un désordre ou d’un état physique
anormal
énumérés à l’annexe A ou à titre de
moyen de guérison.
(2) Il est interdit de vendre à
titre de traitement ou de mesure
préventive d’une maladie,
d’un désordre ou d’un état
physique anormal énumérés à l’annexe A,
ou à titre de moyen de guérison, un aliment, une drogue, un cosmétique
ou un instrument :
a) représenté par une étiquette;
b) dont la publicité a été faite auprès
du grand public par la personne en cause.
|
[…]
|
|
Drugs
|
Drogues
|
9. (1)
No person shall label, package, treat, process, sell or advertise any drug in
a manner
that
is false, misleading or deceptive or is likely to create an erroneous
impression regarding its character, value, quantity, composition, merit
or
safety.
(2)
A drug that is not labelled or packaged as required by, or is labelled or
packaged contrary
to,
the regulations shall be deemed to be labelled or packaged contrary to
subsection (1).
|
9. (1) Il est interdit d’étiqueter,
d’emballer, de traiter, de préparer ou de vendre une drogue — ou d’en faire
la publicité — d’une manière
fausse, trompeuse ou mensongère ou
susceptible de créer une fausse impression quant à sa nature, sa valeur, sa
quantité, sa composition,
ses avantages ou sa sûreté.
(2) La drogue qui n’est pas étiquetée
ou emballée
ainsi que l’exigent les règlements ou
dont l’étiquetage ou l’emballage n’est pas conforme aux règlements est
réputée contrevenir
au paragraphe (1)
|
[24]
Health
Canada’s
enforcement powers are provided by s. 23(1) and s. 26 of the FDA:
23. (1) Subject to subsection (1.1), an
inspector may at any reasonable time enter any place where the inspector believes
on reasonable grounds any article to which this Act or the regulations apply
is manufactured, prepared, preserved, packaged or stored, and may
|
23. (1) Sous
réserve du paragraphe (1.1), l’inspecteur peut, à toute heure convenable,
procéder à la visite de tout lieu où, à son avis, sont fabriqués, préparés,
conservés, emballés ou emmagasinés des articles visés par la présente
loi ou ses règlements. Il peut en outre :
|
(a) examine any such article and take samples
thereof, and examine anything that the
inspector believes on reasonable grounds is
used or capable of being used for that manufacture,
preparation, preservation, packaging or storing;
|
a) examiner
ces articles et en prélever des échantillons, et examiner tout objet qui, à
son
avis, est utilisé —
ou susceptible de l’être —
pour la fabrication,
la préparation, la conservation, l’emballage ou l’emmagasinage de semblables
articles;
|
(a.1) enter any conveyance that the inspector
believes on reasonable grounds is used to carry any article to which section
6 or 6.1 applies and examine any such article found therein and take samples
thereof;
|
a.1) procéder à
la visite de tout moyen de transport qui, à son avis, est utilisé pour le
transport d’un article visé par l’article 6 ou 6.1, examiner l’article qui
s’y trouve et en prélever des échantillons;
|
(b) open and examine any receptacle or package
that the inspector believes on reasonable grounds contains any article to
which this Act or the regulations apply;
|
b) ouvrir
tout contenant ou emballage qui, à son avis, contient un article visé par la
présente loi ou ses règlements;
|
(d) seize and detain for such time as may be
necessary any article by means of or in relation to which the inspector
believes on reasonable
grounds any provision of this Act or the
regulations has been contravened.
[…]
|
d) saisir et
retenir aussi longtemps que nécessaire tout article qui, à son avis, a servi
ou donné lieu à une infraction à la présente loi ou à ses règlements. L’avis
de l’inspecteur doit dans tous les cas être fondé sur des motifs
raisonnables.
[…]
|
26. An inspector who has seized any article
under this Part shall release it when he is satisfied that all the provisions
of this Act and the regulations
with respect thereto have been complied with.
|
26. L’inspecteur,
après avoir constaté que les dispositions de la présente loi et de ses
règlements applicables à l’article qu’il a saisi en vertu de la présente
partie ont été respectées, donne mainlevée de la saisie.
|
[Emphasis
added]
[25]
During
the course of conduct leading to the present Application, Health Canada also
expressed concern about the safety of the composition of EMpowerplus and
whether it met the FDA Regulations. It is agreed that this concern is
not relevant to the present Application.
1.
Events leading to the seizures
[26]
Health
Canada’s warning
letter of April 27, 2001 was the lead event in an adversarial relationship in
which Health Canada attempted to gain TrueHope’s compliance, and to which TrueHope
objected.
[27]
In
response to the April 27, 2001 letter, Mr. Hardy and Mr. Stephan contacted Mr. Dennis
Shelley and Mr. Rob Neske of Health Canada by teleconference to
discuss the issues raised in the letter. As a follow-up to the teleconference, Mr.
Hardy and Mr. Stephan sent a letter to Mr. Shelley
dated June 17, 2002 explaining the merit of
their activities and expressing the desire “that this letter may be only the
beginning of an ongoing dialogue with yourself and others in government who may
have an interest in the health and well being of Canadians specifically those
who suffer the stigma of mental illness”. Attached to the letter were letters
of support from over 200 TrueHope participants and letters and articles from
psychiatrists outlining the “significant” effects of EMpowerplus on users. However,
the fifth page of the letter reads as follows:
Of course, Synergy – Truehope
is not seeking for a product endorsement but rather a clearing of the
roadblocks which impede the progress of this critical research. Legislation
should never be used as an excuse for extending human suffering to protect the
vested interests of a small minority, however powerful that minority might be
perceived.
[…]
We do not feel we should have to
heap embarrassment upon the government nor any of its departments in order to
obtain the confirmation that we are being heard in this request. Nor do we
feel that we should have to stir the ire of thousands of Canadian families who
continue to be aggravated with both the government action and inaction in this
matter to date.
(Applicants’ Record, Vol. 3,
p. 705)
[28]
Health
Canada’s response
to the June 2002 letter came from Mr. Shelly by letter dated December 4, 2002.
Mr. Shelly reaffirmed the continuing FDA and FDA Regulations
violation by Synergy and TrueHope with the statement that “Synergy/Truehope is
required to immediately stop all sale, offering for sale, exposing for sale,
promotion or advertising of E.M.Power+”. The letter concludes by stating that
“FDA compliance is requested not later than the close of business on
December 18, 2002” (Respondents’ Record, Vol. 2, p. 390).
[29]
Mr.
Hardy and Mr. Stephan wrote a responding letter dated December 10, 2002 in
which they mention that they had had telephone conversations with Mr. Shelly on
December 9th, 10th, and 11th and confirmed
that they would attend a meeting with him on January 14, 2003 in the Health
Canada office in Burnaby, B.C. They also made the following statements:
[…]
In light of the content of
your letter of December 4, 2002, we reiterate that it is not our desire to
violate the law. We find ourselves very confused as we had requested
assistance (please see our June 17th letter) from your department as
to what would be acceptable, and have received nothing but a cease and desist
order. Our efforts to set up a meaningful dialogue with your Minister,
requested now three times in writing and with at least a dozen phone calls have
like wise [sic] been met with no response. We are, therefore, very happy to be
able to meet with you.
In the second paragraph of
your letter you indicate that we have a Canadian Website. Please be advised
that there is no Canadian website. The website is now operated in the U.S. by a U.S. corporation.
You also claim that we are in
breach of the law. As we have explained previously, it is our view that we are
not in violation of the Food and Drugs Act. We have provided you with the case
law that indicates that we are not involved in selling a product within Sec. 2
of the Food and Drugs Act.
[…]
(Applicants’ Record, Vol. 3,
p. 932)
[30]
Indeed
the meeting did take place on January 14, 2003 attended by Messrs. Hardy,
Stephan, Shelley, Brosseau, and Ms. Lorill Zandberg who was a TrueHope
participant and EMpowerplus user. A report prepared by Miles Brosseau after the
meeting explains what was discussed. At the meeting, Mr. Stephan and Mr. Hardy
expressed their wishes to be compliant with the FDA with respect to the
sale of their product but also expressed their frustration over the response
Health
Canada gave them to their
request for assistance to ensure their compliance. They also expressed concern
over the clinical trials on EMpowerplus being “sandbagged”. Further, they
requested a Ministerial exemption for their product, adding that they have
tried communicating with the Minister to this effect but were ignored. Ms.
Zandberg attended the meeting to describe her poor experience with prescription
psychiatric drugs and how she had improved with using EMpowerplus. There were
discussions about the way in which sales of EMpowerplus were transacted. Ms.
Zandberg explained that “she paid for the product by cheque written to Synergy”
and “Mr. Stephan stated that since November 2002, cheques for the product are
written to Synergy Group of Canada” (Respondents’ Record, Vol. 2, p. 393).
[31]
Health
Canada representatives at the meeting requested a specific commitment from Mr.
Hardy and Mr. Stephan to comply with the legislation and to stop the sale of
the product in Canada. They also made a suggestion that “Synergy /
Truehope” move its operations to the United States. At the conclusion of
the meeting, Mr. Stephan requested seven to ten days to prepare and submit a
plan of action (Respondents’ Record, Vol. 2, p. 394).
[32]
Following
the January 14, 2003 meeting, Mr. Hardy telephoned Mr. Shelley and told him that
TrueHope would not be able to comply with the Regulations, and that he
was frustrated and wanted to write-up what he was thinking. He asked Mr.
Shelley if he could send his drafted thoughts to Ottawa to which Mr.
Shelley replied he could (Applicants’ Record, Vol. 2, para. 91). As a result, the
next step in the relationship was Mr. Hardy and Mr. Stephan writing an “Open
Letter” to Health Canada on TrueHope letterhead dated March 6, 2003 and
addressed to Mr. Neske:
AN OPEN LETTER TO HEALTH CANADA
March 6, 2003
Mr. Rod Neske, Compliance Officer
Health Canada
Health Products and Food Branch
Inspectorate
3155 Willingdon Green
Burnaby, BC
V5G 4P2
Dear Mr. Neske,
It appears that our letter for
clarification dated June 17, 2002 to Mr. Shelly copied to your Minister and to
Director General Phil Waddington (ONHP) was completely ignored since we
received no response to it whatsoever. In addition to this, we have sent three
letters to your Minister and placed over twenty logged telephone calls to which
we have received no reply either.
Nevertheless, further to our January 14,
2003 meeting in Burnaby, B.C. with Mr. Dennis Shelly and Mr.
Miles Brosseau of the inspectorate, we provide the attached information.
Mr. Shelly has recognized that the
communication with us has not been appropriately handled and has requested that
we outline all of our concerns in letter form and forward them to him.
It is with the continuing desire to
receive a detailed response to our concerns that we submit them to you.
Sincerely,
Anthony F. Stephan David
L. Hardy
Co- Founder Co-Founder
XC: The Honourable Anne McLellan,
Minister of Health.
ATTACHMENT: 6 PAGES
[The Attachment]
PROLOGUE:
Truehope Nutritional Support Ltd. is an Alberta company which has developed a protocol addressing nutrient
deficiencies which are the evident cause of some mental disorders. The
efficacy of the protocol is supported by three peer reviewed publications in
medical journals, as well as a number of studies awaiting publication. Experiential
observation of many doctors worldwide, as well as over 2,500 published studies
showing the positive influence of nutrients on mental disorders, also
contribute to the weight of scientific evidence supporting the discovery.
Truehope offers support to the mentally-ill at no-cost by way of telephone and
internet and also provides free nutrients to the mentally-ill who cannot afford
them. Over four thousand people in Canada have been touched through the use of
this support system. Many of these individuals have been able to find
normality and have returned to their families, careers, and educational
pursuits. Although the supplement has not worked for all who have taken it, an
increasing number of participants are finding total relief from their symptoms.
1. CURRENT CONDITION: Truehope’s
seven-year search for answer to the causes of mental disorders and the ensuing
independent but parallel scientific research has clearly confirmed that
addressing nutritional deficiencies ameliorates symptoms of mental illness
[footnotes omitted]. Our results are consistent with a worldwide movement
towards treating mental illness with natural remedies, a topic that is drawing
much attention in North America (Note: the first ever university conference on
the treatment of mental disorders with nutrient supplementation will take place
at Harvard University on April 25-27, 2003.)
CONCERN: It’s obvious that a government
department entrusted with the health of Canadians should be interested in
fostering, expediting, and assisting such research so clearly important to the
health of Canadians. Instead of investigating and confirming our breakthrough
research, Health Canada has criminalized both the efforts of
Truehope and the University researchers. An Alberta Government funded double
blind study has been shut down at the University
of Calgary and Truehope has
been issued a cease and desist order. Health Canada
employees have shown their bias as demonstrated in comments while turning back
university clinical trial
applications and within their own
internal communications referring to us as “TRUEDOPE” for example. Health Canada has further violated the privacy rights of Truehope and its
founders by releasing confidential information to parties outside of Truehope, without
due process under access to information legislation. Is Health Canada really concerned with improving the access to health for
all Canadians? Are they appropriately respectful of academic freedom in Canada as well as the rights of Canadian citizens?
2. CURRENT CONDITION: Health Canada has issued a cease and desist order against Truehope which
effectively denies to every Canadian the access to our supplement.
CONCERN: For hundreds of Canadians who
have found restored mental health through the Truehope program, this action
denies them their right to health as guaranteed by the Charter of Human
Rights. Such action forces these individuals back onto [sic] less effective
and more dangerous medications (medications that are clearly addictive or which
dramatically increase the risk of cancer or liver or kidney failure for
example. See CONCERN #7). Does this seem to be a responsible action by those
entrusted with the responsibility to ensure the health of Canadians?
3. CURRENT CONDITION: Health Canada is using Schedule “A” and Section 3(1) and 3(2) of the
outdated Food and Drugs Act to eliminate alternative treatments that
effectively alleviate various health concerns.
CONCERN: Over a million consumers across Canada sent a strong message to government in 1997, making it
clear such legislation as Schedule “A” and Section 3(1) and 3(2) of the
antiquated Food and Drugs Act could no longer be used to deny Canadians health
freedom or relegate foods to a drug status. The government responded in
November of 1998 by setting up the Standing Committee on Health which sought
input from citizens across Canada before bringing forward 53
recommendations for change. These recommendations were tabled in the House of
Commons and accepted on March 26, 1999 by the Minister of Health, the Honorable
Allan Rock on behalf of Parliament [footnote omitted]. Further to that process
the government set up the Office of Natural Health Products Transition Team (a
committee of experts formed from Health Canada, consumers and consumer groups) and
accepted their clarification and expansion of the 53 recommendations as
submitted in their March 31, 2000 report
[footnote omitted]. One important segment of the Transition Team report reads
as follows:
Natural Health Products: A New Vision
Section 3 and Schedule A (As They
Currently Stand)
3(1) “No person shall advertise any food,
drug, cosmetic or device to the general public as a treatment, preventative or
cure for any of the diseases or disorders or abnormal physical states referred
to in Schedule A.”
3(2) “No person shall sell any food,
drug, cosmetic or device
(a)
that is represented
by label, or
(b)
that the person
advertises to the general public as a treatment, preventative or cure for any
of the diseases, disorders or abnormal physical states referred to in Schedule
A.”
In Response to the above quoted section
of the act the Transition Team comments:
“Sections 3(1) and 3(2) and Schedule A of
the Food and Drugs Act are no longer relevant. They do not serve any purpose
that cannot be accomplished adequately by other sections of the legislation or
regulations.
More importantly, the schedule does not
reflect contemporary scientific thought. The weight of modern scientific
evidence confirms the mitigation and prevention of diseases and disorders
listed in Schedule A through the judicious use of NHPs. It is time that the
legislation and regulations reflect the prevailing science.
Section 30(1) (m) of the Act grants the
authority to add anything to, or delete anything from, the Schedules of the
Act.
The Transition Team recommends that:
Section 30(1) of the Food and Drugs Act
should be invoked to remove all diseases listed in Schedule A; sections 3(1)
and 3(2) should be revoked through the Legislative Renewal Initiative.”
Health Canada
was then charged with the responsibility to translate these recommendations
from the Transition Team report into law in Gazette1 submitted Dec 22, 2001 and
in Gazette 2 due by June 22, 2003. Glaring omissions in Gazette 1 such as the
recommended elimination of Schedule “A” and Sections 3(1) and 3(2) of the act
and Health Canada’s sudden renewed attempts to enforce
selectively
and unfairly these sections clearly
demonstrate their abrogation of the spirit and intent of the aforementioned
recommendations. Indeed it is difficult to not see this as an attempt on the
part of certain civil servants within Health Canada
to become a law unto themselves, ignoring the will of Canadians by implementing
their own agenda in contempt of parliamentary process. Their actions certainly
fly in the face of the stated intent of Parliament and once again are raising
the ire of consumer groups across Canada. Does Health Canada know something more about the intent of government in this
issue than we are being told?
4. CURRENT CONDITION: Health Canada is imposing sanctions against those who speak the truth
about the effectiveness of nutrient supplements and other alternative health
remedies.
CONCERN: True statements made about the
efficacy of treatments other than pharmaceuticals but which clearly are
supported by the weight of scientific evidence are within every Canadian’s
right of expression according to constitutional law. Health Canada is acting out of synch with the constitutional guarantee
allowing “freedom of thought, belief, opinion, and expression including freedom
of the press and other media of communication” [footnotes omitted]. Isn’t it
time that we hold such rights (outlined in the Canadian Bill of Rights and the
Canadian Charter of Rights and Freedoms) inviolable and amend all old
legislation to so conform [footnote omitted]? In relation to a similar
constitutional consideration, if it’s deemed unconstitutional to deny Canadians
the right to use marijuana (a controlled substance) for medicinal purposes, why
would Health Canada deny Canadians the right to use vitamins
and minerals for the same purpose? [footnotes omitted]
5. CURRENT CONDITION: Health Canada sustains the indefensible position of allowing products to
be sold into Canada without DIN numbers under NAFTA but denies Canadians the
right to produce or sell these same products in Canada.
CONCERN: Such action is a slap in the
face to Canadians who experience this as a clear attempt to legislate an unfair
trade practice, allowing foreign vendors to rob Canadian business. Many of the
products banned in Canada for sale are sold in supermarkets in the
U.S. The fact that these products are
imported into Canada for personal use says that there is no health concern, but
rather Health Canada is involved in a discriminatory trade
practice outside of its stated mandate. In addition, the practice of selective
enforcement of
this discriminatory regulation is proof
that it cannot be administered equitably or fairly. How can Health Canada continue to sustain such a policy?
6. CURRENT CONDITION: Health Canada is making it difficult if not impossible for academic
research to proceed in Canada on products for which there are no
health concerns.
CONCERN: Health Canada is in contempt of the constitutional rights of Canadians by
blocking academic freedom in research and the potential benefit of the research
to the health and well being of all Canadians. They have successfully
terminated a double blind study, using minerals and vitamins, at the University of Calgary which was showing impressive benefits of
nutritional supplementation in the alleviation of psychiatric disorders.
Further, they have held up that research for over a year and a half. Their
attempts to muzzle efforts to educate the public on such important findings are
another breach of constitutional rights and are a discriminatory practice
against the mentally disabled [footnote omitted]. (Section 15 (1) of the
Charter specifically states: “Every individual is equal before and under the
law and has right to the equal protection and equal benefit of the law without
discrimination and, in particular without discrimination based on race,
national or ethnic origin, colour, religion, sex, age or mental or
physical disability”) One must ask why it is Health Canada’s agenda to drive such research out of the country when
expectation from Canadians would be to foster and expand research showing such
promise?
7. CURRENT CONDITION: Health Canada is inadequately informing the public of both the lack of
efficacy and of the significant dangers of psychiatric medications.
CONCERN: The above stated reality is the
very reason for the existence of Truehope. As we have looked into the current
system of treatment of those suffering with mental illness it is little wonder
that so many seek help in vain. Hundreds of studies over the past twenty years
identify the addictive natures and carcinogenic effects of many medications
[footnotes omitted]. (Note: the authors have over 400 studies that
demonstrate the addictive – carcinogenic effects of commonly used psychiatric
medications). Health Canada continues to ignore current research
identifying these realities, hence, the drugs become a significant part of the
problem with many Canadians being put at increased risk by Health Canada’s inaction. We advised you of this in our June 17, 2002
letter and no action was taken to reduce
the risk to Canadians. For a public
service body which is supposedly set up to enhance and protect the health and
well being of Canadians, this could be viewed as a criminal action or a “
Breach of Public Trust” as defined in Section 122 of the Canadian Criminal
Code. Does this seem a responsible act by those entrusted with the
responsibility to ensure the health and well being of all Canadians?
8. CURRENT CONDITION: Truehope exists
because it is literally fighting for the health and well being of family
members of both the co-founders and employees. We have sought clarification in
the past on these issues from both Health Canada and the Minister of Health
with no response whatsoever other than a cease and desist order.
CONCERN: Who is going to be accountable
for the above concerns? Will this letter like all of the other correspondence
to Health Canada be ignored? Who is going to face up to
the reality of mental health treatment in Canada?
CONCLUSION:
In summary it is clear that our work needs to go forward. With evidence
in hand, we therefore demand that the unjust cease and desist order issued by
you to us be immediately rescinded. More important is a similar demand that
you allow research to move ahead unimpeded on our product and every other
product like it where there is a well established history of safety. These
nutrients are not drugs and we and hundreds of thousands of Canadians
demand that you quit treating them as such.
[Footnote References omitted]
[Emphasis in original]
(Applicants’ Record, Vol. 3, pp. 937 - 943)
[33]
In
response to the “Open Letter”, Mr. Hardy and Mr. Stephan received the following
letter from the Executive Assistant to the Minister of Health, Anne McLellan,
dated March 26, 2003:
Mr.
Anthony F. Stephan and
Mr.
David L. Hardy
Co-Founders
Truehope
Nutritional Support Ltd.
P.O.
Box 1254
Cardston, Alberta T0K 0K0
Dear
Mr. Stephan and Mr. Hardy:
On behalf of the Honourable A. Anne
McLellan, I wish to acknowledge receipt of correspondence/communication from
you and representatives from your company, concerning EM-Power - Truehope and
Synergy.
Regulatory compliance and enforcement
action is underway with respect to the sale of drugs by your company.
Therefore, it is inappropriate for the Minister or any member of the Minister’s
staff to discuss the concerns you raise. Regulatory decision-making are
matters that are delegated to departmental officials. Please note that, as of
the date of this letter, any subsequent communication of this nature either by
telephone, facsimile, or e-mail will be forwarded directly to the appropriate
departmental official for response. No reply from the Minister’s office will
be provided.
For your reference, I enclose a list of
regional officials whom you may wish to correspond with concerning compliance
and enforcement actions. I also enclose a list of officials you may wish to
contact to obtain information of a general nature regarding market
authorizations, establishment licensing, and clinical trials.
Under the Food and Drugs Act and
Regulations, manufacturers, distributors, and importers of drugs are subject to
comply with its requirements. Departmental officials will be pleased to assist
you in understanding all regulatory requirements related to your company’s
products.
Thank
you again for writing.
Yours
sincerely,
Hilary
Geller
Executive
Assistant
(Applicants’ Record, Vol. 3, p. 944)
[34]
Mr.
Neske’s response to the “Open Letter” is dated April 8, 2003:
Mr Anthony Stephan
Co-Founder
Truehope Nutritional Support Ltd.
P.O. Box 1254
Cardston, Alberta T0K 0K0
WARNING LETTER
Dear Sir:
This is further to your
correspondence of March 7, 2003 concerning EMPowerplus formerly known as EM
Power Plus and EM Power. Reference in this letter will be made to EM Power and
is intended to apply to all the above names.
Synergy/Truehope continue to
be in violation of the Food and Drugs Act and Regulations due to
promotional activities being conducted at the Lethbridge office. The activities at the Lethbridge office are considered to be
“offering for sale” the product EM Power. “Sell” as defined in the Food and
Drugs Act includes “offer to sell” and “expose for sale” and does not
necessitate possession of any drug product. Please refer to the definition of
“sell” in Section 2 of the Food and Drugs Act.
E.M.Power is considered to be
a drug and a “new drug” as defined by the Food and Drugs Act and
Division 8 of the Food and Drug Regulations. As such, any sale,
promotion and advertising of this product prior to obtaining an [sic] Notice of
Compliance is a violation of this legislation. Furthermore, E.M.Power, and its
suggested dosage, has been reviewed by Health Canada and has been determined to be a Type 2
health risk to Canadians.
Synergy/Truehope must
immediately stop all sale, offering for sale, exposing for sale, promotion or
advertising E.M. Power to Canadians.
Given that the Action Plan
requested at the January 14, 2003 meeting with Mr. D. Shelley explaining how
you intend to comply with the Food and Drugs Act and Regulations
has not been received, the Health Products and Food Branch will be undertaking
further compliance and enforcement activity in keeping with its mandate under
the Food and Drugs Act. Unless future correspondence demonstrates clear
evidence of compliance with the Food and Drugs
Act and Regulations, you should not expect a
reply to every future communication received by Health Canada.
Yours truly,
Rod Neske
A/Operations Manager
(Respondents’ Record, Vol. 2,
pp. 396 - 397).
2.
The seizures themselves
[35]
Two
seizures of EMpowerplus are the subject matter of the present Application.
[36]
The
first seizure was of the April 17, 2003 shipment of 72 bottles of EMpowerplus sent
to Canada by Pharos via
UPS to fill orders from 22 TrueHope participants. The shipment was accompanied
with a Master Invoice and a Consolidated Invoice Detail. The Master Invoice
states where the shipment originated, to whom it was sold, to whom it was to be
shipped, and details of the total quantity of the product shipped with both the
unit value and total value of the products in U.S currency. The Consolidated Invoice
Detail is a breakdown of the Master Invoice, with the total quantity of the
shipment divided into separate invoices addressed to individual buyers or
contacts. Each invoice lists the specific quantity and value of the buyer’s
order.
[37]
The
April shipment was evaluated as follows: as the customs agent for Synergy, UPS
alerted the Canadian Border Services Agency (CBSA) that the shipment was not in
compliance with Canadian laws and regulations including the FDA; the
CBSA consulted with Health Canada to determine next steps by faxing the Master Invoice
and Consolidated Invoice Detail; and, as a result, Mr. Neske recommended that
the shipment be seized because “ Empowerplus is a drug and the fact
that, in my opinion, it was being imported
into Canada for sale”
(Respondents’ Record, Vol. 2, p. 376).
[38]
On
April 28, 2003 Mr. Stephan received a faxed letter from Mr. Neske containing
this message:
Re: E.M. Power +
Further to the shipment of 72
bottles of the above named product presently being detained, this shipment will
not be released at this time. The product is currently under investigation for
importation prohibited under the Food and Drugs Act Regulation A.01.040. We
hope to conclude this investigation quickly with your cooperation.
(Applicants’ Record, Vol. 3,
p. 1034)
Regulation A.01.040 reads as follows:
Subject to section A.01.044,
no person shall import into Canada for sale a food or drug the sale of which in
Canada would constitute a
violation of the Act or these Regulations.
[39]
On
April 29, 2003, Mr. Hardy and Mr. Stephan wrote to Mr. Neske confirming receipt
of his letter:
Dear
Mr. Neske:
We are in receipt of your letter
indicating that the shipment of 72 bottles is being detained and will not be
released at this time. You have indicated the product is under investigation.
This particular shipment has now been detained for eight days, since Tuesday,
April 22, 2003.
Please be advised that your actions in
detaining this product are jeopardizing the health and lives of those persons
who have ordered the vitamin/mineral product EMPOWERPLUS for their personal
health. Many of these individuals have suffered with suicidal symptoms in the
past and your actions are placing them at risk.
We wish to advise you that if any harm
comes to any of those persons, whose product is being detained that we will
seek for CRIMINAL and or CIVIL redress on their behalf against you personally.
The Canadian charter of rights and freedoms, sec 7 states: Everyone has the
right to life, liberty and security of the person and the right not to be
deprived thereof except in accordance with the principles of fundamental
justice. You are effectively denying the rights of life, liberty and security
of those suffering with mental illness by detaining the product shipment.
Govern
yourself accordingly,
Anthony F. Stephan David
L. Hardy
Co-Founder Co-Founder
[Emphasis in original]
(Applicants’
Record, Vol. 3, p. 1035)
[40]
On
May 1, 2003, Mr. Neske, received a demand letter from legal counsel retained by
Synergy and TrueHope requesting “the immediate release of this unlawfully
detained shipment” (Applicants’ Record, Vol. 3, p. 1037). In reply, by letter
dated May 9, 2003, Mr. Neske outlined Health Canada’s lawful conduct with
respect to the seizure pursuant to s. 23 and s. 26 of the FDA and
confirming that the shipment would not be “released immediately” as requested (Applicants’
Record, Vol. 3, p. 1039). The April shipment was formally seized on May 8, 2003
by completion of a “Report of Examination for Customs Entry” (Applicants’
Record, Vol. 4, p. 1203).
[41]
The
second seizure was of the May 16, 2003 shipment of 57 bottles of EMpowerplus
and three bottles of EMpowerplus powder. While Inspector Sandra Jarvis
initially seized this shipment on the same basis as the April shipment, she
later released it on her own interpretation of the Master and Consolidated Invoice
Detail that the product was not being imported into Canada for sale. As
a
result, Ms. Jarvis notified UPS that Health
Canada no longer had an objection to importation of the shipment (Respondents’
Record, Vol. 2, p. 331).
[42]
However,
over the next number of months, several shipments of EMpowerplus were deemed to
be in violation of the FDA and Regulations, and, consequently, individuals
named on the Consolidated Invoice Detail who ordered the product received a
letter notifying them that the shipment was refused entry into Canada (Applicants’
Record, Vol. 4, pp. 1043 - 1185).
3.
Events subsequent to the seizures
[43]
At
the time of the seizures there were some 48,000 users of EMpowerplus in 50
countries (Applicants’ Record, Vol. 1, p. 26) many of whom were dependent on
EMpowerplus as a treatment for a mental disorder. A number of discrete actions
were taken for the purpose of pressuring Health Canada to end its restriction
on access to the product: users engaged in a massive letter writing and telephone
calling campaign to government officials; the support of Member of Parliament,
Dr. James Lunney, was solicited to act as an advocate for the users and lobbied
government on behalf of the users; and a group of women users called the “Red
Umbrellas” publicly declared that, by travelling to Parliament Hill in Ottawa
to demonstrate, speak to Members of Parliament, and holding a press conference,
their health was being jeopardized
[44]
To
deal with user telephone complaints, Health Canada set up a
1-800 Crisis Line. According
to data produced by Health Canada tracking the calls received
by the 1-800 Crisis Line, a
total of some 484 calls were received between June 2, 2003
to June 25, 2003 (Hearing Exhibit No. 1 filed November 10, 2009).
[45]
As
a result of the actions taken, on March 18, 2004 an “Agreement” was reached
between Health Canada and TrueHope to formally allow users then, and now, to
import EMpowerplus directly from Pharos in Utah under the “Personal Use
Importation Directive” (PUID); orders for personal use are placed directly with
Pharos, the money to pay for the orders is transmitted directly to Pharos, and the
orders are allowed to come across the border unimpeded. EMpowerplus is
available for sale in the United States without restriction.
Health Canada takes the
position that its mandate is to only restrict sales of the product in Canada in
the interest of public safety and it does not have a legal interest in the use
of the product if it is lawfully brought into Canada for personal
use. However, to enforce the existing restriction of sale of EMpowerplus in Canada, under the
PUID only a three-month supply of the product is allowed to be imported.
[46]
With
respect to access to EMpowerplus, the Agreement has resulted in peace between
Health Canada and TrueHope
to the present day. There is no evidence that this condition will not continue
to be in effect into the future.
II. The User
of EMpowerplus Aspect of the Charter Challenge
[47]
From
the early development of EMpowerplus in 1998 to the time of the seizures, TrueHope
had achieved a high degree of marketing success: people by the hundreds if not thousands
had become dependent on the product for their mental health treatment. It is
this group of people that
Mr. Hardy feels responsibility for, and it
is this group of people to whom the present Application is intended to serve.
[48]
In
service of users of EMpowerplus for a therapeutic purpose, an objective of the
present Application is to establish that EMpowerplus does treat the underlying
mental illness for which it is taken. Mr. Hardy made this admission in the
course of examination on his affidavit:
That's why this case is so significant,
because -- either it's true, either we're telling you the truth, which I swear
that we are, or -- and this is a major breakthrough and a great benefit to
humanity in the future, your kids and my kids; or this is a hoax and needs to
be exposed. So I hope this court case does that, but if it is the case, that
this is a breakthrough, then we want to see it pushed forward.
(Applicants’ Record, Vol. 5, p. 1414)
[49]
The
Applicants’ ultimate objective is to force an amendment to the seizure sections
themselves to address the wrong which is described in paragraph 43 of the Notice
of Application:
Seizures under section 23 of
the [FDA] have the effect of removing drugs, Natural Health Products or
medical devices from individuals that rely upon them for their health or very
lives. Such seizures deny individuals:
a. sovereignty over their own
bodies;
b. the right to treatments of
their choice;
c. access to effective
treatments, and
d. the right not to have
effective treatments removed without a consideration of the health risks of
removing the treatments.
(Applicants’
Record, Vol. 1, p. 9)
The effect of the wrong in the
circumstances of the present Application is described as follows:
As a result of the seizures,
other users of Empowerplus are deprived of access and secure access to Empowerplus,
which product provides the nutritional balance for their health and alleviates
the symptoms of their mental conditions. Their health and mental well-being
were
severely compromised by the
seizures and they feared uncertainty in future supply.
As a result of the seizures,
Hardy was deprived of access and secure access to Empowerplus, which provides
the nutritional balance for his family members, some of whom suffer from mental
illness.
As a result of the seizures,
Hardy and other users of Empowerplus suffered serious psychological stress.
As a result of the seizures,
the physical and/or mental health of Hardy and other users of Empowerplus was
put in jeopardy.
(Applicants’ Record, Vol. 1,
p. 7, paras. 27 to 31)
The Applicants argue that, to correct the
wrong, a due process feature must be introduced into the operation of s. 23 to
provide that a judicial hearing be conducted before a vital health product is seized.
The object of the hearing would be to provide an opportunity to a user,
potentially deprived of a vital health product by the seizure, to make an
argument. The argument would be that a health risk will result to him or her if
the seizure takes place, and if this argument is well received by the judicial
officer conducting the hearing, the seizure would not be allowed. The nature of
the hearing that will meet this expectation is proposed to be some form of warrant
process either by teleconference or in person (Hearing Transcript, Vol. 13, pp.
3249 – 3272).
[50]
As
a result, paragraphs 74, 94, and 95 of the Notice of Constitutional Question propose
questions with respect to s. 23 and s. 26 as they relate to Section 7 and
Section 8 Charter rights of the Applicants as well as the Section 7
rights of users of EMpowerplus for a therapeutic purpose. Paragraph 74 reads as
follows:
1. Whether it is vital to a system of
justice for the Respondents to
take away products people rely on for
their health without:
a. considering the health risk of
removing the products, and
b.
a review mechanism to challenge the seizure and detention
2.
whether it is vital to our system of justice for persons with no health
training to be making decisions that directly impact upon health;
3.
whether the State has the right to have effective treatments removed without
compelling reasons to justify the removal;
4.
whether the State has the right to detain essential health products
indefinitely without any review or judicial oversight;
5.
whether the risk of removing Empowerplus exceeded the risk of leaving it on the
market (this is the balancing of the individual and State interests);
6.
whether the seizure and detention powers which violate s. 8 of the Charter
can be considered to be in accordance with the principles of fundamental
justice;
7.
whether the seizure and detention powers which violate the principles of
procedural fairness can be considered to be in accordance with the principles
of fundamental justice;
8.
whether the seizures and detention violated the criminal negligence provisions
of the Criminal Code R.S.C. 1985 c. C-46;
9.
if the seizures and detention were criminally negligent, whether they could be
considered to be in accordance with the principles of fundamental justice.
Paragraphs 94 and 95 read as follows:
When addressing whether a seizure is
unreasonable within the meaning of s. 8, the Court must consider whether the
harm caused by the seizure is excessive in relation to the harm sought to be
avoided by making the seizure
It is not “reasonable” within the meaning
of s. 8 of the Charter to seize and detain products that people rely
upon for their health:
(1)
without
any notice;
(2)
without
any mechanism to review the seizure and continued detention;
(3)
without
balancing the health risk of the seizure and detention against the interest to
be served by the seizure and detention;
(4)
without
any prior authorization;
(5)
by persons
who are not qualified to assess the health risks of the seizure, and/or
(6)
in
violation of s. 7 of the Charter.
The Applicants argue that answers to these
questions in their favour will result in a finding that s. 23 and s.26 are
unconstitutional. However, the focus of the argument is on the health risk to
users, and the infringement of the life, liberty and security Charter rights
of users and, therefore, the evidence which will support the argument can only
come from users who make a personal Charter claim. With respect to the
present Application, Mr. Hardy is not a user of EMpowerplus for a therapeutic
purpose and, therefore, has no claim to make and no evidence to offer as a
user. The success of the argument depends on a determination with respect to
the nature of a constitutional challenge launched pursuant to s. 52 of the Constitution
Act, 1982.
[51]
Counsel
for the Applicant argues that a claim that a provision is unconstitutional
because it breaches a Charter right pursuant to s. 52 of the Constitution
Act, 1982 is different in kind to a claim for relief under s. 24 of the Charter
for breach of a Charter right: that is, the former is not a claim for a
remedy and, therefore, is not limited by the nature of an Applicant’s personal
claim. These provisions are as follows:
Enforcement
24.
(1) Anyone
whose rights or freedoms, as guaranteed by this Charter, have been infringed or
denied may apply to a court of competent jurisdiction to obtain such remedy
as the court considers appropriate and just in the circumstances.
|
Recours
24. (1) Toute
personne, victime de violation ou de négation des droits ou libertés qui lui
sont garantis par la présente charte, peut s’adresser à un tribunal compétent
pour obtenir la réparation que le tribunal estime convenable et juste eu
égard aux circonstances.
|
General
52. (1) The Constitution of Canada is the supreme law
of Canada, and any law that
is
inconsistent with the provisions of the Constitution is,
to the extent of the inconsistency, of no force or effect.
|
Dispositions générales
52. (1) La
Constitution du Canada est la loi suprême du Canada; elle rend inopérantes
les dispositions
incompatibles de toute autre règle de droit.
|
[52]
With
respect to this argument there are two issues to address: Mr. Hardy’s legal
ability to rely on the evidence of users to somehow add to his own personal
claim the risk to life or liberty or security of users; and his legal ability
to have the Charter claims of users considered as a feature of his own
personal claim.
A. The Applicants’
argument
1. The legal
ability to add to a personal claim
[53]
In
written argument, Counsel for the Applicants frames Mr. Hardy’s legal ability
to add to his own personal claim this way:
The striking down of
legislation affects not only the parties, but the public at large. It is
inappropriate to strike down legislation based on a narrow fact pattern
specific to the parties in a review, without considering the effect of the
decision broadly (see paragraph 181). Similarly, courts must look at both the
"purpose" and the "effect" of the legislation in
determining its constitutionality (see discussion beginning at paragraph 175).
This obligation to consider the broad effect of the legislation dictates a
broad review of effects beyond those on the parties.
A fuller discussion of the
scope of evidence mandated in this review follows the ss. 7 and 8 analysis.
However, in considering the evidence relevant to ss. 7 and 8, it is important
to note that it was open to the applicants to lead evidence of the effect of
the law on others that is unconnected to the seizures and detentions under
review. So for example, the Applicants could have led evidence of seizures
with no connection to the Applicants to demonstrate that the "effect"
of the law is unconstitutional. It just happened in this case that there was
ample evidence of the broad "effect" of the law on others with a
factual nexus to the seizures under review. Such a factual nexus is not a
requirement for "effect" evidence. The only requirements are that
courts should not make constitutional determinations on the effect of
legislation without broad "effect" evidence, and there is an
obligation on the party seeking to have legislation struck to lead such
evidence.
[…]
There is no question there
has been an infringement of life liberty or security of the person. As indicated above, to get
past the first hurdle, it is only necessary to show on a balance of
probabilities that there has been an infringement of life, liberty or
security of the person. In this case it is clear that there has been an infringement
to life, liberty and security of the person. The seizures and
detentions were likely to impair health. The right to make fundamental health
decisions was clearly interfered with. The right
of access to a treatment was
interfered with. The State's action caused severe psychological stress. The
real issue is whether these infringements occurred in accordance with the
principles of fundamental justice.
[Emphasis in the original]
(Applicants’ Record, Vol. 20,
Memorandum of Fact and Law, paras. 111, 112, 124)
Thus, as the argument goes, evidence of the
infringement of the right to life, liberty, and security of “others” who are
not themselves Charter claimants, can be imported into Mr. Hardy’s
personal right to security Charter claim to expand the merit arguments
of his claim.
2. The
legal ability to allow the Charter claims
of non-Applicants
to be considered
[54]
With
respect to Mr. Hardy’s legal ability to allow the Charter claims of
users to be considered as a feature of his own personal claim, in oral argument
at the hearing of the present Application, Counsel for the Applicants advanced
the proposition that, because Mr. Hardy has standing to advance his personal
Section 7 challenge, it is possible to use this standing to argue a Charter
breach of each of the Section 7 rights and the Section 8 right of other persons
who are not a party to the present Application. This category of other persons
is argued to be: the 21 users of EMpowerplus, apart from Mr. Hardy, who have a
property interest in the product seized; three users who have filed affidavits
in the present Application attesting to the beneficial effect that the product
has had on their mental health and expressing concern for their health if
deprived of the product; and all users who relied on the product at the time of
the seizures and who complained to Health Canada as part of the campaign to end
the enforcement action. This argument is based on a second
proposition: with respect to a
constitutional challenge pursuant to s. 52 of the Constitution Act, 1982,
the effect of the seizures on Mr. Hardy as an Applicant is irrelevant and what
is relevant is the effect on the users.
B. The
Respondents’ argument
[55]
Counsel
for the Respondents argues that there is no difference in kind between a Charter
claim brought under s. 24 of the Charter and one brought under s. 52 of
the Constitution Act, 1982. Either claim is a claim for relief and the
same legal rules with respect to standing and evidence applies. In oral
argument, this submission was made:
We submit the
case has to be decided on evidence specific to the parties; that this case
falls under the general rule of standing whereby a person alleging infringement
of a Charter right has standing to plead that infringement and is limiting to
asserting a breach of his own rights. Cases need to
be resolved on evidence specific to the parties. The scope is properly limited
to the Charter rights of the parties. The failure of a diffuse challenge or a
wide-spread challenge could prejudice other challenges to the same rules by
parties, which specifically and factually are able to establish complaints. It
always must be kept in mind that the evidence heard has to be from -- in
relation to the parties most affected by the decision. Someone who is
affected who is not a party has no standing, and their complaint cannot be
voiced through a party with standing. To do so, it would compromise the need
for Charter cases to be decided in a proper factual context.
[Emphasis added]
(Hearing
Transcript, Vol. 10, pp. 2326 - 2327)
[56]
With
respect to the s. 52 arguments under consideration, Counsel for the Respondents’
position with respect to both is as follows:
This judicial review is about whether or
not the seizure, or the law permitting the seizure, violated the rights of the
Applicants. It is not an abstract exercise as to whether or not the
seizures, or the law permitting the seizures, might violate:
(a)
the rights of others
not party to this judicial review;
(b)
the rights of others
to any natural health product; or,
(c)
the rights of others
to anything regulated by the Food
and Drugs Act.
The references to “others” in the
Applicants’ application and evidence, purporting to show impacts or effects on
others, is not relevant to the issues in this proceeding. The impacts or
effects on others are not proper contextual elements to consider in the
adjudication of the Charter claims raised by the Applicants.
As an Applicant, Hardy can not meet his
burden of proof of establishing a limit to his own rights without evidence
of the effect of the law or action on his own rights. Hardy does not allege
that he relies on Empowerplus to treat an illness.
The proper scope of this judicial review
is to determine whether or not government actions or legislation violated the Applicants’ Charter
rights. Standing to bring a Charter challenge may be granted under four
broad heads. First, the general rule is that a party alleging an infringement
of their Charter rights and freedoms, has standing to plead those Charter
infringements, but are limited to asserting a breach of their own rights and
not those of others.
Second, where a party has been brought
involuntarily before the courts, the party may, as of right, challenge the
constitutionality of the statute under which the party is being prosecuted: R.
v. Big M Drug Mart and Canadian Egg Marketing Association (“CEMA”),
infra. Third, a court may exercise its discretion to grant standing where
the test for public interest standing has been met. Fourth, a court may grant
standing under a residual discretion in respect of matters of national
importance: CEMA, infra. Thus while R. v. Big M Drug Mart
Ltd., and CEMA, infra, provide exceptions to the general rule, those
exceptions do not apply in this case.
[Case citations omitted]
The requirement of a full and proper
evidentiary record in constitutional cases is nonetheless limited to evidence
that is relevant
to the adjudication of the claims before
the court. Thus, evidence about the effects of the impugned government actions
or legislation on others who are not before the court is not required. The
Applicants’ evidence - that there was an impact on others in a variety of
circumstances, is not relevant to Hardy’s and Truehope’s claims. On this
basis, it is not admissible.
[Case citations omitted]
The issue in this judicial review is
about the impact of [Health Canada Inspector] Neske’s seizure and detainment
[of the April 2003 shipment], pursuant to sections 23(1)(d) and 26 of the FDA,
on the Applicants. The issue is not about the hypothetical potential impact
that a warrantless seizure under section 23(1)(d) may occasion.
In addition, [Health Canada Inspector]
Jarvis’ initial recommendation to Customs to refuse entry [of the May 2003
shipment] does not implicate the seizure power under section 23(1)(d) of the
2003 FDA or s. 26 of the FDA. There was no seizure in this instance that
withheld the product from the Applicants or any other consumer.
[Emphasis
in the original]
(Respondents’
Record, Vol. 19, pp.127 - 129)
C. Analysis
of the arguments
[57]
As
a rule, a Charter challenge is only available to a person. However, in R. v. Big M Drug Mart
Ltd.,
[1985] 1 S.C.R. 295 (Big M Drug Mart) the Supreme Court allowed a criminal law exception
to this rule by providing standing to a corporation to maintain a Section 2(a)
challenge to the constitutional validity of the legislation which compelled it
to Court. In Big
M Drug Mart
the reasoning of Chief Justice Dickson is provided at
paragraphs 36 - 41:
Standing and jurisdiction to
challenge the validity of a law pursuant to which one is being prosecuted is
the same regardless of whether that challenge is with respect to ss. 91 and 92
of the
Constitution Act, 1867, or with respect to
the limits imposed on the legislatures by the Constitution Act, 1982.
Section 24(1) sets out a
remedy for individuals (whether real persons or artificial ones such as
corporations) whose rights under the Charter have been infringed. It is
not, however, the only recourse in the face of unconstitutional legislation. Where,
as here, the challenge is based on the unconstitutionality of the legislation,
recourse to s. 24 is unnecessary and the particular effect on the challenging
party is irrelevant.
Section
52 sets out the fundamental principle of constitutional law that the
Constitution is supreme. The undoubted corollary to be drawn from this
principle is that no one can be convicted of an offence under Section 52 sets
out the fundamental principle of constitutional law that the Constitution is
supreme. The undoubted corollary to be drawn from this principle is that no one
can be convicted of an offence under an unconstitutional law. The respondent
did not come to court voluntarily as an interested citizen asking for a
prerogative declaration that a statute is unconstitutional. If it had been
engaged in such "public interest litigation" it would have had to
fulfill the status requirements laid down by this Court in the trilogy of
"standing" cases (Thorson v. Attorney General of Canada,
[1975] 1 S.C.R. 138, Nova Scotia Board of Censors v. McNeil, [1976] 2
S.C.R. 265, Minister of Justice of Canada v. Borowski, [1981] 2 S.C.R.
575) but that was not the reason for its appearance in Court.
Any
accused, whether corporate or individual, may defend a criminal charge by
arguing that the law under which the charge is brought is constitutionally
invalid. Big M is urging that the law under which it has Any accused, whether
corporate or individual, may defend a criminal charge by arguing that the law
under which the charge is brought is constitutionally invalid. Big M is urging
that the law under which it has been charged is inconsistent with s. 2(a)
of the Charter and by reason of s. 52 of the Constitution Act, 1982,
it is of no force or effect.
Whether a corporation can
enjoy or exercise freedom of religion is therefore irrelevant. The respondent
is arguing that the legislation is constitutionally invalid because it impairs
freedom of religion--if the law impairs freedom of religion it does not matter
whether the company can possess religious belief. An accused atheist would be
equally entitled to resist a charge under the Act. The only way this question
might be relevant would be if s. 2(a) were interpreted as limited to
protecting only those persons who could prove a genuinely held religious
belief. I can see no basis to so limit the breadth of s. 2(a) in this
case.
The argument that the respondent, by
reason of being a corporation, is incapable of holding religious belief and
therefore incapable of claiming rights under s. 2(a) of the Charter,
confuses the nature of this appeal. A law which itself infringes religious
freedom is, by that reason alone, inconsistent with s. 2(a) of the Charter
and it matters not whether the accused is a Christian, Jew, Muslim, Hindu,
Buddhist, atheist, agnostic or whether an individual or a corporation. It is
the nature of the law, not the status of the accused, that is in issue.
[…]
[Emphasis
added]
[58]
However,
the “effect on the challenging party is irrelevant” phrase emphasized in the
passage just quoted is the basis of an interpretation argument made by Counsel
for the Applicants in response to the Respondents’ argument that the Charter
rights of “others” cannot be brought into the present Application. Counsel for
the Applicants gave the following explanation in oral argument:
And the Applicants' position is, is that
the case law is crystal clear. Well, for instance, we have the Applicant
Truehope, we have the Applicant David Hardy. And the Applicants are absolutely
crystal clear that when you're challenging constitutionality of legislation
under Section 52 of the Constitution, and very important, Section 52, and
that's -- we've listed that in our Notice of Application, that not only must
the Court look at the purpose and effect, but so broadly that it's to look at
the purpose and effect of others.
And the reason for that is quite simple,
if a party could come before you and show a personal Charter violation and ask
the Court to strike down the law as unconstitutional, but the laws have an
application to everyone. And so courts are not supposed to strike down laws as
unconstitutional under Section 52 without having an appreciation of broad
purpose and effect.
Often what happens is some people can
bring an application under Section 24 of the Charter, which is a personal
thing. They have to show personal violation before the Court can grant a
remedy. But
under Section 52 that's not necessary.
And so, I'd like the Court to refer to tab 193. Now, this is Big M again. And
this is a very important point. So I've just referred to Big M where they said
purpose and effect. You need to look at purpose and effect.
And now, this is where, at paragraph 38,
the Court is drawing this distinction between when you're seeking relief under
Section 24 of the Charter and you're seeking relief under Section 52. So at
38:
Section 24(1) sets out a remedy for
individuals whether real persons or artificial ones, such as corporations,
whose rights under the Charter have been infringed, is not, however, the only
recourse in the face of unconstitutional legislation, whereas here the
challenge is based on the unconstitutionality of the legislation, recourse to
Section 24 is unnecessary, and the particular effect on the challenging party
is irrelevant.
And I cannot stress this more. So what
the Supreme Court of Canada is saying here is, yeah, Section 24 of the Charter,
that's an avenue that people have for relief. And usually you're applying to
have evidence excluded, it's used in criminal trials all the time, and a lot of
my friend's case law, they're Section 24 cases. But it's absolutely crucial
for the Court to appreciate what we're applying for here is a declaration under
the authority of Section 52 of the Constitution, which is the section that
basically says the Constitution is the supreme law of Canada, and any law that is inconsistent with it is of no force
and effect. And I do reproduce that in mine.
So the Supreme Court of Canada here is
making clear, and I've emphasized it and marked it in red: That when you're
challenging the constitutionality of the legislation, recourse of 24 is
unnecessary, and the particular effect on challenging party is irrelevant.
So what that means is, is I don't have to
show the Court that Mr. Hardy's personal rights were violated. I don't have to
show that Truehope's rights were violated. And -- but I can't -- now, this is
the case that says you have to show purpose and effect. So when they're saying
we have to show the effect, well, they're not talking about the effect on Big
M.
Sorry, they carry on in paragraph 39:
Section 2 sets out the fundamental
principle of constitutional law that the constitution is supreme. The undoubted
corollary to be drawn from this principle is that no one can be convicted of an
offence under an unconstitutional law. The Respondent did not come to Court
voluntarily as an interested citizen asking for a prerogative declaration that
a statute is unconstitutional.
Now, this is an early case that began
this principle, and everyone agrees back in 1985 when this came out, this only
applied to if you were charged. So a corporation could challenge the
constitutional validity of legislation if they're charged. This has now been
expanded, and I'll show that.
[Emphasis added]
(Hearing Transcript, Vol. 3, pp. 760 –
765)
[...]
Well if you have to look at the effect
and the effect on the challenging party doesn’t matter, well, the effect on who
then is the obvious question, and it’s clear it’s the effect on others.
(Hearing Transcript, Vol. 3, pp. 777 –
778)
[59]
I
reject this argument. I find that the “effect on the challenging party is irrelevant” phrase
has been given a meaning which can only be derived by reading it out of
context. The
leading words of the passage in which the phrase is stated sets the context; that
is, the words “where as here” must be read as referring to the situation being
addressed in the case which is, where a person or a corporation is facing a
criminal prosecution the personal circumstances of the person or the
corporation are irrelevant because the whole focus is on the constitutionality
of the law upon which the prosecution is based.
[60]
There
is no question that where the constitutionality of legislation is in issue, the well established
principle that the "purpose" of the
legislation must be defined, and the "effect" of legislation challenged
on Charter grounds must be broadly considered before a determination is
made; it is not contested that the effect of the legislation, beyond the effect
on the parties, must be considered (see Big M Drug Mart, para. 80;
Mackay v. Manitoba, [1989] 2 S.C.R. 35 at para. 9). Therefore, application
of the principle is an evidentiary imperative in determining a
constitutionality issue. However, Counsel for the Applicants seeks to somehow
extend this evidentiary principle to establish a right of legal standing in a
constitutional challenge.
[61]
Counsel
for the Applicants cites the following cases for the point that, in each,
insufficient effect evidence was provided to succeed in a constitutional
challenge of the legislation concerned: Mackay v. Manitoba, [1989] 2
S.C.R. 357, R. v. Edwards Books and Art Ltd., [1986] 2 S.C.R. 713, Danson
v. Ontario (Attorney
General),
[1990] 2 S.C.R. 1086 and R. v. Rao (1984), 46 O.R. (2d) 80. The argument
arising from these cases as an “expansion” of the ratio in Big M Drug Mart
is that the principle that sufficient effect evidence must be produced allows
the evidence of the effect on “others” to somehow give standing to the “others”
to maintain their own personal Charter claims in an application to which
they are not a party. In my opinion, this is an erroneous use of the principle.
The evidentiary principle has nothing whatever to do with the legal principle
that standing must be first established before a person can maintain a Charter
challenge.
[62]
The
“expansion” argument also relies on what I find to be an unsupportable interpretation
of the decisions in R.
v. Parker
(2000), 188 D.L.R. (4th) 385 (Ont.C.A.) (Parker) and R. v. Morgentaler, [1988] 1 S.C.R. 30 (Morgentaler).
[63]
In Parker,
the Ontario Court of Appeal found that: the epileptic defendant, who was
charged with possession of marijuana contrary to s. 4 of the Controlled
Drugs and Substance Act, S.C. 1996, c. 19, used marijuana for medicinal
purposes and therefore was forced to choose between a life-threatening health
condition and the threat of imprisonment; the marijuana prohibition impaired
Parker’s Section 7 rights; and the prohibition impaired the rights of others
who use marijuana for medicinal purposes. It is this last finding upon which
Counsel for the Applicants puts reliance to argue that the decision in Big M Drug
Mart
is expanded to conclude that the “onus under Section 52 is to show Charter violations
and it can be Charter violations of other people and it can be Charter
violations of yourself” (Hearing Transcript, Vol. 3, p. 787). The finding in Parker,
read in context, is in paragraphs 77 to 80:
In the
companion case of R. v. Clay, I have already dealt with the submission
that, broadly speaking, the marihuana prohibition violates s. 7 because it
criminalizes people who have done nothing wrong. This case raises the narrower
issue of the impact upon individuals claiming a need for marihuana as a matter
of medical necessity, not recreational use.
This
aspect of the case raises an issue akin to the standing issue that I have
touched upon in the Clay case. The Crown's approach to this appeal was
to try to demonstrate that as a matter of fact Parker did not need marihuana to
control his epilepsy. I deal with that issue below. However, it is also open
to Parker to challenge the validity of the legislation on the basis that it was
overbroad or unconstitutional in some other way in its application to other
persons. The Crown respondent appeared to concede this in the Clay appeal.
In any event, that conclusion follows from the
decisions
of the Supreme Court of Canada in R. v. Big M Drug Mart Ltd., [1985] 1 S.C.R. 295 and R. v. Morgentaler. In both cases, the
accused were held to have standing to challenge the law under which they were
charged although the alleged infringement of the Charter concerned the rights
of some other person.
The
decision of the Supreme Court of Canada in Morgentaler is of particular
assistance because the issues in that case were similar to the issues here. The
accused physicians relied upon s. 7 of the Charter to challenge a criminal
offence based upon the interference with the health of pregnant women seeking
abortions. In his dissenting reasons at p. 133, McIntryre [sic] J.
suggested that the question of the s. 7 violation was hypothetical since,
"[t]here is no female person involved in the case who has been denied a
therapeutic abortion". However, Dickson C.J.C. was satisfied that the
accused physicians had standing. As he said at p. 63:
As an
aside, I should note that the appellants have standing to challenge an
unconstitutional law if they are liable to conviction for an offence under that
law even though the unconstitutional effects are not directed at the appellants
per se: R. v. Big M Drug Mart Ltd., at p. 313. The standing of the
appellants was not challenged by the Crown.
Therefore,
it is open to Parker to challenge the validity of the marihuana prohibition not
only on the basis that it infringes his s. 7 rights because of his particular
illness, but that it also infringes the rights of others suffering other
illnesses.
[Emphasis
added]
In my opinion it is clear that neither Parker nor Morgantaler
expands upon the decision in Big M Drug Mart to serve the purpose of
Counsel for the Applicants’ argument.
[64]
Indeed,
an attempt is made to obtain a finding that Mr. Hardy is in the situation of a
person compelled to challenge the constitutionality of the seizure provisions
of the FDA on two grounds: he was not a volunteer in bringing the
present Application because he felt the responsibility to do so to
the benefit of users of EMpowerplus and he
had no other choice but to do so to gain the return of his EMpowerplus seized
in the April 2003 shipment. The decisions in Canadian Egg Marketing Agency v. Richardson, [1998] 3 S.C.R. 157 (CEMA)
and
PCL Industrial Constructors Inc. v. CLR
Construction Labour Relations Association of Saskatchewan Inc., [1999] S.J.
No. 151, (Sask. Q.B.) (PCL)
are advanced in support of this argument.
[65]
In
oral argument, Counsel for the Respondents submitted that Mr. Hardy is not in
the role of defendant or in a position to challenge a law that is alleged to be
in breach of someone else’s Charter rights. Therefore, Mr. Hardy is not
compelled to act in the present Application in the same way as were the
respondents in CEMA and Big M Drug Mart.
[66]
While Big
M Drug Mart provided an exception for criminal law, the Supreme Court in CEMA
expanded the exception to civil proceedings. The Respondents in CEMA
are private poultry producers who challenged the constitutionality of the
federal egg marketing scheme. At paragraph 34, Justices Iacobucci and
Bastarache wrote:
The
constitutionality of the federal egg marketing scheme is clearly an issue of
national importance, as are the more specific issues raised with regard to
whether ss. 2(d) and 6 of the Charter apply to corporations.
These issues were addressed in the courts below and could have been dealt with
by this Court based on this residuary discretion. However, this case has
provided this Court with an opportunity to revisit the rules governing the
granting of standing to a corporation under the so-called Big M Drug Mart exception.
Prior to this decision, the respondents could not obtain standing to invoke
the Charter using the exception created by this Court in R. v. Big M
Drug Mart Ltd., [1985] 1 S.C.R. 295, because they were not facing penal
proceedings. In our opinion, it is now time to expand the exception to allow
corporations to invoke the
Charter
when they are defendants in civil proceedings instigated by the
state or a state organ pursuant to a regulatory scheme.
However, the exception was provided with the following
caution at paragraph 44:
Our
expanding the Big M Drug Mart exception to civil proceedings in these
limited circumstances is not intended to provide corporations with a new weapon
for litigation. The purpose of the expansion is to permit a corporation to
attack what it regards as an unconstitutional law when it is involuntarily brought
before the courts pursuant to a regulatory regime set up under an impugned law.
Surely, just as no one should be convicted of an offence under an
unconstitutional law, no one should be the subject of coercive proceedings
and sanctions authorized by an unconstitutional law.
[Emphasis added]
[67]
In PCL the Court found that a
number of industrial contractors were required to commence the action for a
determination of issues that pertain to their rights and obligations under the
existing statutory labour relations regime and, under these circumstances,
determined that the plaintiffs have standing to invoke the Charter on
the basis of the principles set out in CEMA.
[68]
Counsel
for the Applicants argues that TrueHope can obtain standing as a corporation to
invoke the Charter by using CEMA, and also argues that the
findings in PCL establish that plaintiffs, not under threat of criminal
or civil regulatory sanction, can be compelled to bring a civil action and gain
standing to make a constitutional Charter argument. I find that this
argument is irrelevant because, in my opinion, the present Application was
brought and has been maintained purely as a matter of choice.
[69]
The
seizures were a clear signal from Health Canada that talking about TrueHope’s and
Synergy’s failure to comply with the law was no longer an option. In the face
of this fact, Mr. Hardy had choices to make: stop offering EMpowerplus for sale
by re-arranging TrueHope’s and Synergy’s marketing practices; or attack the
seizures by Court action. Obviously, the latter choice was made.
[70]
Access to
EMpowerplus has been provided to users under the March 2004 “Agreement” and, as
mentioned, there is no evidence on the present record that this fact will
change into the future. Therefore, one might question the rationale for
maintaining the Application in view of this fact. The detention of the
EMpowerplus seized in the April 2003 shipment as a practical matter is
inconsequential. During the course of the hearing, Counsel for the Applicants
stated that the rationale for maintaining the present Application is to ensure
“secure” access because access under the Agreement is still at the “whim” of
Health Canada (Hearing Transcript, Vol. 13,
p. 3143).
[71]
Thus, from
the way that the Application has been structured and argued, it is apparent
that introducing due process into the existing seizure provisions of the FDA is
a primary rationale for maintaining the Application. In my opinion, advancing
this rationale is, again, purely a matter of choice: operate within the law willingly,
or operate within the law under objection and attempt to change the law.
Obviously, the latter choice was made.
[72]
In
conclusion, I find that Counsel for the Respondents’ argument on the law of
standing is correct. Thus,
I
find that Mr. Hardy’s standing can only be used for the purpose of bringing his
own
personal Section 7 and Section 8 challenges
on the evidence of the direct impact the seizures had upon him. I make a
similar finding with respect to TrueHope’s Section 8 challenge.
[73]
As
a result, I find that the evidence with respect to Charter claims of the
users of EMpowerplus is irrelevant to the present Application.
D. Do s.
23 and s. 26 of the FDA offend Section 7 and 8 of the Charter?
[74]
As
set out above, the Constitutional Question framed by the Applicants attacks
both s. 23 and s. 26 as offending Sections 7 and 8 of the Charter on the
same basis. The argument is framed this way:
This case will also address
whether it is permissible to seize and detain vital health products
indefinitely for regulatory violation without Court supervision.
(Applicants’ Record, Vol. 20,
Memorandum of Fact and Law, para. 110)
As mentioned, the focus of the
constitutional challenge argument is on the health risk to users, and the
infringement of the life, liberty and security Charter rights of users
and, therefore, the evidence which will support the argument can only come from
users who make a personal Charter claim. Because the Charter
claims of users of EMpowerplus have been found to be irrelevant to the present
Application, I find that the answer to the question posed is “no”.
III. The
Relevance of Contested Affidavit Evidence
[75]
The
Applicants and Respondents have filed cross motions to strike certain
paragraphs of the affidavit evidence on the principal grounds that the evidence
is hearsay or inadmissible opinion. In the course of the case management
process leading to the hearing of the present Application, I directed that the
determination of the admissibility of the contested affidavit evidence would be
resolved in the final decision for the reason that a contextual understanding
of the evidence would be necessary before a final determination could fairly be
made.
[76]
Much
of the contested evidence has been tendered in anticipation that the Charter
claim evidence of non-Applicant users is relevant to the present Application. The
determination of the narrow scope of the present Application as found in the
preceding Section of these reasons has rendered this evidence as irrelevant. I
find that both the Respondents’ and the Applicants’ strike motions can be dealt
with on this basis. The law with respect to the relevance and admissibility of
evidence is as follows:
Facts in issue, which are
sometimes called “principal” facts, are those necessary by law to establish the
claim, liability or defence, forming the subject-matter of the proceedings; and
which are in dispute between the parties [footnote omitted].
[…]
Relevancy must be distinguished from admissibility,
of which, though the primary, it is by no means the sole condition. Evidence
may be relevant and yet, on grounds of convenience or policy, inadmissible.
Indeed, this exclusion of matter otherwise relevant has been called the
distinguishing feature of the English law of evidence. It is correct then, in
deciding whether evidence is admissible, to ask first whether the evidence is relevant
and, thereafter, whether there are any rules or discretions, based on
convenience or policy, which nonetheless make this relevant evidence inadmissible.
[Emphasis in the original]
(Phipson on Evidence, 16th
Ed. (London: Sweet and Maxwell, 2005), paras. 7 –
02, 7 – 05)
Further, the Ontario Court of Appeal decision
in R. v. Truscott, [2006] O.J. No. 4171 at paragraphs 22 and 23 is
instructive:
Evidence is relevant if, as a matter of
logic and human experience, it renders the existence or absence of a material
fact in issue more or less likely […]. Evidence will be irrelevant either if it
does not make the fact to which it is directed more or less likely, or if
the fact to which the evidence is directed is not material to the proceedings.
Relevance is contextual in that it
depends on the facts in issue, the position taken by the parties in respect of
those facts, and the other evidence adduced in relation to those facts: see R.
v. Arp (1998), 129 C.C.C. (3d) 321 at 338 (S.C.C.). Because relevance is
contextual, a court will often be unable to determine relevance at the time the
evidence is proffered, but will receive the evidence conditionally and
determine the relevance of the evidence after the evidentiary picture has been
fully developed. It does not follow, however, that because relevance often
cannot be determined when the evidence is tendered, that relevance should not
be addressed when the evidence is tendered. If a court is satisfied when the
evidence is tendered that the evidence is irrelevant, it should so hold and
refuse to admit the evidence. A court should not hear evidence on the chance
that it might somehow, at some time, in some way become relevant in the proceedings.
[Emphasis added]
A. The
Respondents’ motion to strike the Applicants’ evidence
[77]
The
evidence of the factual history underlying the present Application recounted in
the affidavits of Mr. Hardy, Mr. Stephan, and Mr. Lunney is uncontested as relevant.
I find that any
other evidence tendered by either Mr.
Stephan or Mr. Lunney in support of the concerns of users is irrelevant.
[78]
Mr.
Hardy’s state of mind is a fact in issue in the present Application and,
therefore, evidence with respect to this fact is relevant. In his affidavit,
together with his factual statements, Mr. Hardy provides opinions and hearsay
evidence with respect to the entire context of the story under review,
including the development of EMpowerplus, the conduct of TrueHope, his
relationship with Health Canada and his relationship with users of EMpowerplus,
including members of his family and Mr. Stephan’s family. I find that this
evidence is relevant as proof of his state of mind, but for no other purpose.
Because Mr. Hardy refers directly to Landon Hardy’s mental health experience in
support of his own Charter claim, I find that the affidavit evidence of
Landon Hardy is relevant, but only as recounted below in Section IV, (A), (3),
(d).
[79]
While
it is an undisputed fact that users of EMpowerplus report an improvement in
their mental health as a result of taking a recommended dosage of the product,
controversy exists as to whether EMpowerplus treats mental illness and is,
therefore, “efficacious”, or whether EMpowerplus merely creates a placebo
response because it is expected to treat, and is, therefore, only “effective”.
Given the limited scope of the present Application as found, I find that the
question does not constitute a fact in issue because it can only be advanced if
the Charter rights of users are in play. This was the strategy advanced
by the Applicants, but it has failed.
[80]
As
a result I find that the following affidavit evidence is irrelevant: the
evidence of Ms. Coulson and Ms. Oxby which goes to prove the positive effect
that EMpowerplus has had on their lives; the evidence of Mr. LaJeunesse, a past
executive with the Canadian Mental Health Association, which goes to support
user claims; and the expert opinion evidence of Dr. Kaplan, a psychologist, and
Dr. Popper, a psychiatrist, which goes to the treatment effect of EMpowerplus.
[81]
With
respect to the 1-800 Crisis Line notes, there is no disagreement that the notes
prove that a certain number of calls were received voicing concern about the
seizures, and while this fact is relevant as an element of the history
evidence, the truth of the content of the calls is irrelevant. I make the same
finding with respect to the audio and video recordings of users which includes
the testimonials of the Red Umbrellas.
[82]
With
respect to the Applicants’ application to admit the in-court testimony of Mr.
Miles Brosseau, a Health Canada official, given in the Provincial Court of
Alberta criminal trial of TrueHope and Synergy for breach of the FDA
Regulations, to prove that Health Canada did not consider the health
consequences of the April 2003 seizure before making the seizure, I find that
this fact is not contested.
B. The Applicants’ motion
to strike the Respondents’ evidence
[83]
As
stated above, it is agreed that Health Canada’s expressed concern about the
safety of the composition of EMpowerplus is not relevant to the present
Application. The Applicants object to certain elements of the affidavits of
Health Canada officials
who address this irrelevant concern as
well as the irrelevant treatment effect of EMpowerplus.
As a result, I find that the affidavit evidence of Dr. Duc Vu, Director of
Marketed Biologicals, Biotechnology and Natural Health Products Bureau with
Health Canada, Dr. Robin Marles, Director of the Bureau of Clinical Trials and
Health Sciences with Health Canada, and Dr. Siddika Mithani, an Associate
Assistant Deputy Minister with Health Canada, is irrelevant.
[84]
For
the same reason applied to the expert evidence of Dr. Kaplan and Dr. Popper
with respect to the Respondents’ strike motion, I find that the expert evidence
of Dr. Silverstone, a psychiatrist, which also goes to the treatment effect of EMpowerplus,
is irrelevant.
C. Conclusion
[85]
I
find that the evidence found to be irrelevant is inadmissible.
IV. The Personal
Aspect of the Charter Challenge
A. Mr. Hardy’s
Section 7 challenge
[86]
Section
7 of the Charter reads as follows:
7. Everyone has the right to life,
liberty and security of the person and the right not to be deprived thereof
except in accordance with the principles of fundamental justice.
|
7.
Chacun a droit à la vie, à la liberté et à la sécurité de sa personne; il ne
peut être porté atteinte à ce droit qu’en conformité avec les principes de
justice fondamentale.
|
[87]
Mr.
Hardy is not a user of EMpowerplus for a therapeutic purpose and, thus, he
cannot
argue that the seizure sections are unconstitutional as a denial of health
products necessary for his life or a denial of his liberty to choose necessary
vital health products.
[88]
Therefore,
the focus of Mr. Hardy’s Charter challenge is with respect to his right
to security. His subjective and objective claim is that his emotional well-being
as a security interest has been infringed by the seizures. His standing to make
this argument is not contested.
1. The test
to be met
[89]
I
find that the proper correct legal approach to evaluating Mr. Hardy’s claim
involves a critical analysis of not only his subjective evidence but also relevant
objective evidence with respect to the content of his subjective claim in order
to determine the weight to be given to his subjective evidence. This point is
made clear in New Brunswick v. G.(J.), [1999] 3 S.C.R. 46 at paragraph
60:
For a restriction of security of
the person to be made out, then, the impugned state action must have a
serious and profound effect on a person's psychological integrity. The
effects of the state interference must be assessed objectively, with a view to
their impact on the psychological integrity of a person of reasonable
sensibility. This need not rise to the level
of nervous shock or psychiatric illness, but must be greater than ordinary
stress or anxiety.
(Emphasis added)
[90]
As
identified in this passage, a strong subjective and objective evidentiary base
is required to prove the breach claimed.
[91]
The
impugned state action which is in issue in the present Application is the April
and May, 2003 seizures; however, I accept Counsel for Mr. Hardy’s submission
that, viewed in context, the relevant objective evidence with respect to the
seizures begins with the circumstances leading to the development of EMpowerplus
and ends with the Agreement in March 2004.
[92]
Thus,
the question is: did the seizures, understood in context, have a serious and
profound effect on Mr. Hardy’s psychological integrity?
2.
The objective evidence
[93]
The
objective evidence is the history recounted above in Section I.
[94]
On
the objective evidence, a number of facts can be found: the seizures took place
within an adversarial relationship between Mr. Hardy and Health Canada; within
this battle of wills Mr. Hardy was a full and competent participant; Mr.
Hardy’s refusal to comply with Health Canada’s lawful demands caused anxiety on
both sides; and Health Canada and Mr. Hardy were both frustrated by the fact
that no progress could be made to resolve the existing conflict.
[95]
It
is clear on the evidence that Mr. Hardy was representing the interests of users
of EMPowerplus; however, he was doing so as the principal of a corporation that
had an economic interest in maintaining a profit from the sale of a product, the
profit being necessary to maintain the company and efforts of its operatives,
as well as the counselling program developed.
[96]
On
the evidence, the seizure was a defining moment in the enduring conflict, but
it was one which could have been predicted and should have been expected. In
particular, the challenge presented by Mr. Hardy should have been understood by
him as an open invitation to Health Canada to take enforcement
action. It is very understandable that the tone and content of the “Open Letter”
was a challenge to the authority of Health Canada that could
no longer be tolerated. Indeed, Health Canada’s response
made it clear that the negotiation process was at an end and the enforcement
process was about to begin. The response was ample notice that a likely step in
this new phase of the relationship would be seizure.
3.
The subjective evidence
[97]
There
is no evidence upon which to question Mr. Hardy’s credibility or his stated motives
with respect to operating TrueHope and Synergy or the engagement with Health Canada. Precisely
with respect to Mr. Hardy’s state of mind in the course of this conduct, there
are three sources of information the credibility of each is not in doubt: Mr.
Hardy’s own evidence, Mr. Stephan’s evidence, and the evidence of Mr. Hardy’s
son, Landon Hardy.
[98]
The
affidavit evidence supplied by Mr. Hardy and Mr. Stephan makes constant
reference to the two of them acting together. For example, each affidavit uses
the plural pronoun “we” with respect to actions they took together. With
respect to Mr. Hardy’s state of mind, there are similar references with respect
to their joint states of mind; for example, in speaking about Mr. Neske’s
letter of April 28, 2003, Mr. Stephan says that the letter “caused us a lot of
anxiety” (para. 99), and “we were so concerned about the health of TrueHope
Participants…” (para. 100). Thus, while Mr.
Stephan supplies confirming evidence, I put
primary weight on Mr. Hardy’s own evidence with respect to his own state of
mind.
[99]
Landon
Hardy is the only user of EMpowerplus to whom Mr. Hardy directly refers in his
affidavit and who has filed an affidavit in the present Application. Because of
their close association, I find that Landon Hardy’s own evidence is content of
Mr. Hardy’s state of mind; indeed, he also provides evidence confirming Mr.
Hardy’s evidence.
[100] In his October 4, 2008
affidavit filed in the present Application (Applicants’ Record, Vol. 2, pp. 292
– 322) and in the examination conducted thereon, Mr. Hardy makes a number of
statements to prove his state of mind in support of his Charter claim.
a. A duty to help people
who need and use EMpowerplus
[101] By 2002, Mr.
Hardy and Mr. Stephan were committed to developing EMpowerplus out of a sense
of duty. Mr. Hardy makes this point under examination when speaking about
treating Mr. Stephan’s children:
[…] that’s what we set out to do, is just
put together a product. I don’t know that we had in mind to make a big company
out of it, but we knew we had one obligation, and that was to keep those kids
whose lives were at stake, stable, and that was the thrust of it. If you have
ever lived with the hell of mental illness, you’ll know that it’s one of the
most devastating experiences of life, and that’s where Tony [Stephan] had been,
and that’s where we didn’t want to ever go back to; and what has largely driven
us is the fact that we don’t want others to have to experience that either.
(Applicants
Record, Vol. 5, p. 1400)
[102] With respect
to this and the circumstances of users, throughout there is no question that
Mr. Hardy functioned on a belief that the product is efficacious in successfully
treating mental illness. The purpose here is to understand this factor in play as
a contributor to his state of mind. Whether, in fact, EMpowerplus is
efficacious or merely effective is irrelevant.
[103] Mr. Hardy
expresses his belief in his affidavit as follows:
We have always felt we have a
moral duty to help people suffering from mental illness who approach us for
help. I have witnessed over the years a success rate of over 80% of people
suffering from bi-polar disorder who join our Program experience either a total
or a substantial reduction in their symptoms. The majority of Participants who
were on psychiatric medications when joining the program were able to get off
of those medications or to substantially reduce them and at the same time have
a total or substantial reduction in their symptoms. Many participants, like Mr.
Stephan’s children Joseph and Autumn were unable to effectively manage their
symptoms on psychiatric medications but have a complete elimination of symptoms
on EMpowerplus.
It is my personal belief that
if at any time, including the present, we stopped providing EMpowerplus that we
would witness suicides and hospitalizations of TrueHope Participants. We would
also witness the return of debilitating symptoms despite interventions by
doctors and psychiatrists. I believe I would witness people close to me such as
my son Landon, or Mr. Stephan’s children Autumn and Joseph return from living
healthy lives to being disabled by mental illness.
(Applicants’ Record, Vol. 2,
p. 300 at paras. 37 and 38)
b. Frustration
with Health Canada
[104] From the
outset, as he explained under examination on his affidavit, Mr. Hardy knew very
well that he would be held accountable for selling EMpowerplus in Canada:
[…] Q: Any time
after 2000 when Dr. Peterson sent that letter, which is Exhibit 13, and the
short time after, were you concerned
that the fact
that the product, according to Health Canada, did not comply with
the actual regulations, that some steps might be taken to take the product off
the shelves or off the market, as you've said?
A: Yeah, I
think when we got those letters, that we were definitely aware and concerned of
what might happen. That's why we started writing letters and trying to get
meetings with Ministers, all of which -- very few of which were responded to
appropriately. We didn't get any answers and we couldn't get meetings. We
definitely were aware that there was a problem. We just didn't know how to
rectify it. And I wasn't prepared to terminate it and wait for six years while
Health Canada determined
that I could finally have it back for my son, who would be dead by then.
(Applicant’s Record,
Vol. 5, p.1454)
[105] However, with
respect to Health Canada’s April 27, 2001 demand to stop selling EMpowerplus,
Mr. Hardy in his affidavit expresses the following concern:
We were not actually
distributing the product in Canada and consequently did not
believe we needed an establishment licence. The product was manufactured and
shipped in the United
States. We were
willing to work with Health Canada to modify what was said on
our website to address their [sale in Canada]
concerns and so I hoped at the time that we could address that concern. […]
We were concerned about [Miles
Brosseau’s] demand to stop selling. Our primary concern was that if we stopped
selling we believed that we would cause serious harm to the Participants in the
TrueHope program.
(Applicants’ Record, Vol. 2,
p. 309, paras. 80 and 81)
[106] In the letter
of June 17, 2002 as described in the history above, Mr. Hardy expressed frustration
at not being able to get Health Canada to listen to his
concerns. The reply which came six months later and the meeting which followed
on January 14, 2003 proved that Mr. Hardy and
Health Canada were in a
stalemate. Mr. Hardy makes this comment in his affidavit with respect to the
meeting:
At the January 14, 2003
meeting Miles Brosseau suggested that we move to the United States. We thought about that option and
reached the conclusion that it was not feasible. Assuming the United States would allow us to emigrate
and re-locate, we concluded that it was not economically feasible to do . We
were also worried about finding and training new people to run the TrueHope
Program if we relocated.
(Applicants’ Record, Vol. 2,
pp. 311 - 312, para. 90)
[107] With respect
to the Minister of Health’s March 26, 2003 reply to the “Open Letter”, Mr.
Hardy makes the following comment:
[…]
This letter was difficult to
deal with. We believed that the Minister had the power under the Act to grant
us an exemption so that EMpowerplus would remain available. We had repeatedly
brought up the ministerial exemption option in our correspondence and meetings
(for example in our June 17, 2002 letter or at the January 14, 2003 meeting).
We were now being told by the Minister’s Office that the Minister would not
meet with us, let alone grant us an exemption.
[…]
(Applicants’ Record, Vol. 2,
p. 312, para 92)
c. Anxiety caused by
the seizures
[108] Mr. Hardy expresses his
concerns about the effect of the seizures on his family as follows:
I have never suffered from
mental illness. However, after we developed EMpowerplus I began taking it
regularly as a vitamin and mineral supplement. I have encouraged the rest of my
family to do the same. I have not experienced any negative effects. Indeed, my own
experience is that I feel well and seem to get things like colds and flues with
less frequency than when I was not taking EMpowerplus.
When, as described below,
Health Canada seized the April 17, 2003
shipment of 72 bottles of EMpowerplus, they seized 15 bottles that I had
ordered for myself and my family. For myself and most of my family this seizure
was not going to create a health risk. However, for Landon and Cherilea, this
seizure did create a significant health risk. Landon and Cherilea depended upon
EMpowerplus for their mental health and stability. The seizure threatened this.
I became very worried for the health of Landon and Cherilea when my order of
EMpowerplus was seized. I was very concerned that I might have to witness my
children revert to the psychiatric ward or worse. By that time I had plenty of
experience with others becoming unstable very quickly when they quit taking
EMpowerplus. I took the seizure as nothing less than a threat to their lives.
(Applicants’ Record, Vol. 2,
p. 302, paras. 46 and 47)
However, because Mr. Hardy was fully
aware of the PUID, under examination on his affidavit he admitted that members
of his family were not deprived of access to the product as a result of the
seizures because he was personally able to bring a sufficient supply into Canada under the PUID (Applicants’
Record, Vol. 5, p. 1440 - 1442).
[109] Mr. Hardy was also
concerned about the deprivation of other users of EMpowerplus; in his affidavit
at paragraph 97 he states that the April seizure also “caused us great concern
as we feared for the health of the persons whose shipments were detained”. With
respect to Mr. Neske’s letter of April 28, 2003 stating that the April shipment
would not be released, in his affidavit Mr. Hardy gives his reasons for
responding as he did in his April 29th letter:
The April 28, 2003 letter
caused us a lot of anxiety. The 15 bottles of mine that were seized were for my
family, some of whom used EMpowerplus to control serious mental illness. The
other 57 bottles were for 21 separate TrueHope Participants, many of whom had
suffered from severe mental illness before using EMpowerplus. We believed that
this detention posed a significant threat to the health and safety of these 21
Participants and my family. We responded
promptly with a letter dated
and sent on April 29, 2003 to communicate our concerns.
[…]
The purpose of the letter was
to clearly communicate to Health Canada
that they were creating a serious health risk by detaining the shipment. We
believed that his dangerous action was a violation of the Participant’s section
7 rights under the Charter and we wanted Health Canada to consider this. We hoped that by sending
this letter Health Canada would realize that they were
creating a dangerous situation and release the shipment.
We were so concerned about the
health of the TrueHope Participants whose EMpowerplus was seized, that we
sought legal help […].
(Applicants’ Record, Vol. 2,
pp. 314 - 315, paras. 99 and 100)
[110] Following the
April seizure, Mr. Hardy states:
For much of this period TrueHope
was flooded with calls from TrueHope Participants who were worried that they
were not going to get EMpowerplus. Many of the calls were from Participants who
had not yet had shipments seized, but who called to communicate to us they were
worried. Many of the callers were in a panic. […]
We felt obligated to do
everything we could to change Health Canada’s
mind and to ensure that TrueHope Participants could access EMpowerplus.
We also decided to publicize
what was happening and the steps we were taking in an effort to create
political pressure on the Government to allow access to EMpowerplus.
(Applicants’ Record, Vol. 2,
pp. 317 - 318, paras. 114, 116, and 117)
d. Concern
about Landon Hardy’s condition
[111] Landon Hardy gives
the following description of his mental condition, its treatment, and his
reaction to the seizures:
The first problems I recall having were at
age 17, in late 1997, around exam time. I recall having racing thoughts that
would keep me awake at night, and paranoid thoughts that armed government or
military people were coming to get me, and that helicopters were coming after
me. The symptoms got worse over the next few months.
I suffered perhaps my worst psychotic
episode in March 1998. My symptoms got to a point that I felt trapped and
wanted to escape, so I bolted from the house. I thought I could run all the way
to see my brother who was in Russia. I put on two or three
housecoats, several pairs of shoes and other pieces of clothing, and ran out of
the house. I ran through town, across fences, through fields, across a highway,
and through an irrigation canal filled with broken ice and knee deep water. I
recall throwing snowballs at some horses, and waving at cars on the highway. As
I became hot from running, I started to throw off my clothing. After running a
fair distance, I ran up to a house that was unfamiliar to me and knocked at the
door. By that time, I was naked. The residents of the house appeared shocked,
but handed me a blanket. Just when I was at the door, my father and brother
showed up, and also the police. I do not know who called the police, but I
noticed a woman in the house on the telephone. My father and brother were able
to calm me down, and took me home. Fortunately, the police did not lay any
charges.
I also recall that I became
very psychotic for a few days and could not sleep. One particularly bad night,
March 20, 1998, I had two or three songs in my head, all at the same time,
which I could not shut off. I was hallucinating, and thought there were saws
trying to cut me in half, snakes biting me, and that I was being chased by
helicopters. My parents brought me into their room to try to calm me down.
Eventually I got through the episode. However, I did not feel well enough to go
back to school, so I stayed home and tried to recuperate.
My father suggested that I try
taking four supplements, on a consistent program, that he was involved in
manufacturing. Given the seriousness of my behaviour, and how frightening the
experiences of my breakdown had been, I agreed to try the supplements. Slowly,
my state of mind improved. After four or five months on the program, I started
to feel better. The racing thoughts slowed down, and the frightening images
went away. I was calmer, and could sleep. I did not have an urge to escape
from something.
I was well enough to go back
to school in September, and finished my year and graduated. I was careful to
keep on the supplement program, and felt completely normal. I functioned very
well for a year and one half.
In February 2000, my father provided
me with a newly formulated supplement to try, Empower-plus, produced by Evince,
at Cornerstone Labs. I understood this formulation to be more stable than the
previous one.
I started on this program before
I traveled to Salt
Lake City, Utah,
for a missionary project I was involved with. After a few weeks, I moved to Toronto for the project. I found this
work very time consuming, and often was out for many hours of the day. I was
doing really well. I was very involved in my work, and started to get careless
with taking the supplement. I began to think that my problems were behind me
and that I did not need to continue taking the supplement. I was skipping the
lunch time doses, and just sporadically taking the EMPowerplus.
Just before I left Ontario, I caught a gastroenteritis,
which gave me diarrhoea. This went on for a few weeks, and any EMPowerplus that
I did take would not have been absorbed. I returned to Alberta in December, back to my parents home.
The diarrhoea continued for a few more weeks. I found that I was feeling worse
and worse and that I was quick to lose my temper. I found I got more and more
angry, and the outbursts got worse. I began to have disturbing hallucinations,
the same images as in 1998, but they were more violent. My thought processes
were not coherent, and I was not functioning well. I recall periods of extreme
anger, I began to lose control, and at one point, I recall smashing a chair in
an angry rage. I set a couple of fires in the house. My parents could no longer
cope with my behaviour, and took me into the Raymond Hospital, on February 5, 2001, where I
was certified as a formal patient under the Mental Health Act, and moved to Lethbridge Regional Hospital.
[…]
I was diagnosed with
schizophrenia. In the hospital I was given Flanksol for the first month, and
later put on Haldol. I was also put on Zyprexa. I recall some anger outbursts
in the hospital, such as flipping over a puzzle table. I threw a piece of pizza
at another patient. I wanted to get out, but they would not let me leave.
Initially,
I felt worse, but after the
doctors changed the medication, I stabilized somewhat. I slept up to 18 or 20
hours at times. […]
I gained 50 – 65 lbs. on the
hospital medications and I felt that my brain was in a fog. I found that
although my thoughts were no longer racing, I was drowsy. I did not actually
feel better. I was not violent anymore, and found myself feeling very mellow.
However, I did not feel functional. On the EMPowerplus, I do not have the
drowsiness, and I feel functional.
After I was in the hospital
for a time, I started back on EMPowerplus. My family would bring it in for me,
and there were two nurses who reminded me to take it. I recall that I told the
treating physicians at the hospital that I was on EMPowerplus.
After I was released from the
hospital, I continued taking the supplement, and was careful with my diet to
avoid bowel problems, and eventually went off the Zyprexa. I went back to the
psychiatrist who treated me in hospital six months later to follow up. I was
not having any problems at all, and I have not gone back. I have had no
relapses since that time. I have never stopped taking EMPowerplus as I do not
want to ever go back to the psychiatric ward or to experience the racing
thoughts, confusion, paranoia, or hallucinations again.
In April 2003, I heard through
my family that the government had seized shipments of EMPowerplus. When I heard
that the shipments had been seized at the border, I became extremely anxious,
and fearful of what could happen to me and my family if I were unable to obtain
the EMPowerplus. I have experienced severe mental illness and, since being on
the EMPowerplus program, I have been completely healthy and well. After I
became ill in 1997, and started on the EMPowerplus in 1998, I only had one
relapse or breakdown, just after I completely stopped taking the EMPowerplus
around December, 2000.
I was still single, and living
in the family home with my parents in 2003. I know that I threatened my family
and was a danger to myself back in early 2001, and I was fearful of becoming
ill again. I could see that the seizure of the EMPowerplus shipments at the
border caused my parents a great deal of stress and concern, as I had been
violent with them in the past when I was not taking the supplement. I also saw
that my parents were angry and frustrated about the seizures.
(Applicants’
Record, Vol. 8, pp. 2345 - 2449, paras. 6 – 13, and 15 - 20)
e. Conclusion
[112] The principal impression
that arises from Mr. Hardy’s evidence is that he is a strong, dedicated,
creative, and very determined person. At the time of the seizures he filled
many roles: entrepreneur with substantial business development and management
skill; visionary leader and supporter of the use of natural health products for
a therapeutic purpose; challenger of government authority perceived to be
unfair and uncaring; dedicated supporter of persons in need of mental health
care; and supportive and caring father of his own unwell children.
[113] The evidence
of activity within each of these roles is difficult to separate. The evidence
of Mr. Hardy’s disappointment and frustration as a builder of a successful and trusted
natural health care business in the challenging atmosphere of conflict with
government regulation is difficult to separate from the evidence of his
personal feelings of caring and concern for users of EMpowerplus who felt
threatened by the seizures.
[114] I have no
doubt that throughout Landon’s life, Mr. Hardy suffered a great deal of
emotional anxiety over his son’s poor mental health, and that the seizures
produced some immediate fear for his son’s safety. However, with respect to
Landon’s continuing access to EMpowerplus after the seizures, when viewed
realistically and on the basis of Mr. Hardy’s own evidence, Landon’s access was
never in doubt. Mr. Hardy knew of options to assure supply, and, in fact, did
take up these options to ensure supply.
[115] With respect
to the seizures, Mr. Hardy’s resilience is impressive. His immediate response
was to help facilitate and manage a very successful campaign to provide
continuing access to EMpowerplus for TrueHope participants through an agreement
with Health Canada. Indeed, in
an effort to secure access into the future, as a principal in TrueHope and as
an Applicant in these proceedings, he has fought hard during the past six years
to bring his health care concerns to hearing through the present Application.
[116] Therefore,
given Mr. Hardy’s proven strong character, and given the complexity of the
factors in play in the history of TrueHope’s and Mr. Hardy’s experience with
Health Canada leading to the seizures as described, I cannot find that the test
for Mr. Hardy’s Section 7 challenge has been met; I cannot find that the seizures,
understood in context, had a serious and profound effect on Mr. Hardy’s
psychological integrity.
[117] Thus, I
dismiss Mr. Hardy’s Section 7 Charter claim.
B. Mr. Hardy’s
and TrueHope’s Section 8 Charter challenge
[118] Section 8 of
the Charter reads as follows:
8. Everyone has the right to be
secure against unreasonable search and seizure.
|
8. Chacun a droit à la
protection contre les fouilles, les perquisitions ou les saisies abusives.
|
[119] It is agreed
that only the seizure of the April 2003 shipment is relevant to the present
Section 8 claim because, while the May 2003 shipment was inspected, in the end
result it was not in fact or law seized.
[120] The recent
law with respect to determining whether a “seizure” engages a Section 8 right
is expressed by Justice Lebel at paragraph 53 of the Supreme Court’s decision
in Quebec (Attorney
General) v. Laroche, [2002] 3 S.C.R. 708 (Quebec v. Laroche):
However,
just as an overbroad interpretation of the word "seizure" might
defeat the purpose of s. 8, so too might a strict literal interpretation of
that concept. In interpreting the word "seizure", we cannot look only
at the process. We must examine the context and the objective of the guarantee.
By ignoring the purpose and context of the provision, we might deprive it of
part of its effect in numerous situations in which constitutional interests in
privacy, not to mention the regularity and fundamental fairness of criminal
procedure, are in issue. Accordingly, if there is to be any limit on the
definition of the word "seizure", it must not relate to the process per
se, but rather to the context in which it is carried out. The issues
involved in interpreting and applying s. 8 are clearly explained in the
following comments by S. C. Hutchison, J. C. Morton and M. P. Bury:
One
limitation ought to be put on the scope of "seizure" under the
Charter. The "enjoyment of property" as a specific right, as
protected in the Canadian Bill of Rights, is not protected in the Charter. The
prohibition of unreasonable search and seizure is designed to promote privacy
interests and not property rights. Hence, Charter protections against
unreasonable seizure should not apply to governmental actions merely because
those actions interfere with property rights. Specifically, where property
is taken by governmental action for reasons other than administrative or
criminal investigation a "seizure" under the Charter has not
occurred. A number of cases illustrate this view of seizure. A detention
of property, in itself, does not
amount
to a seizure for Charter purposes -- there must be a superadded impact upon
privacy rights occurring in the context of administrative or criminal
investigation.
[Emphasis
added]
(S. C.
Hutchison, J. C. Morton and M. P. Bury, Search and Seizure Law in Canada
(loose-leaf), at p. 2-5; see also: F. Chevrette and H. Cyr, "La protection
en matière de fouilles, perquisitions et saisies, en matière de détention, la non-rétroactivité
de l'infraction et la peine la plus douce", in G.-A. Beaudoin and E. Mendes, eds., The
Canadian Charter of Rights and Freedoms (3rd ed. 1996), 10-1, at pp. 10-8
and 10-9).
Therefore, a contextual analysis is
required to determine the purpose of the seizure: was it for criminal
investigation as argued by the Applicants; for administrative investigation as
argued by the Respondents; for both purposes; or for neither purpose?
[121] The
Applicants’ primary argument is that this Court has already determined that FDA
seizures are for the purpose of criminal investigation. The following passage at
paragraph 150 of Justice Muldoon’s decision in C.E. Jamieson v.
Canada, [1988] 1 F.C. 590 (C.E. Jamieson), which focussed on
the predecessor provision to s. 23, is relied upon as support for this
argument:
It is true that paragraphs 22(1)(a), (b)
and (c) create powers which appear to provide for regulatory inspections, but
paragraph 22(1)(d) which the inspectors invoked, provides that such official
"may ... seize and detain ... any article by means of or in relation to
which he reasonably believes any provision of this Act or the regulations has
been violated". (Emphasis added.) Those are the words in which section 26
is expressed. The legislative intent to make paragraph 22(1)(d) an
enforcement adjunct to the prosecution of offences pursuant to section 26 is
too clear to merit further discussion.
[Emphasis added]
Given the requirement for a contextual
analysis in answering the question as stated by Justice Lebel in Quebec v.
Laroche, with respect, I find that the evidence on the record of the
present Application does merit further discussion about Health Canada’s reasons
for performing the seizure.
[122] In the course
of the examination on his affidavit, Mr. Neske provided a policy directive containing
the following statement with respect to enforcement of the FDA and the FDA
Regulation by way of seizure:
6.5.12. Seizure and Detention
An administrative seizure and detention
is an immediate enforcement tool for controlling non-compliance. The
Inspectorate may take control of non-compliant articles (eg. drugs or medical
devices) under the authority for administrative seizure and detention provided
in the applicable legislation. When determining whether to implement an
administrative seizure and detention, the Inspectorate will consider the risk
to health and safety and the compliance history of the regulated party.
Evidentiary seizures are used to gather
evidence for a prosecution. The Inspectorate may seize non-compliant articles
as evidence under the authority of a search warrant obtained pursuant to
section 487 or 489 of the Criminal Code as evidence.
6.5.13. Prosecution
A prosecution is a legal proceeding in
which the courts determine whether the applicable legislation has been
contravened and if so, apply an appropriate penalty. The Inspectorate will
consider recommending that charges be laid if non-compliance:
• creates a significant health or
safety risk;
• is continuing in nature;
• was premeditated, indifferent,
reckless or a marked departure from a reasonable standard of care;
• other enforcement activities have
proven unsuccessful.
(Applicants’
Record, Vol. 8, p. 2589)
Thus, as a matter of practice, the policy make
a clear distinction between an “administrative seizure and detention” as an
immediate enforcement tool for controlling non-compliance and an “evidentiary
seizure” used to gather evidence for a criminal prosecution.
[123] Indeed, in May 2004, TrueHope
and Synergy were criminally charged with contravention of the FDA and
the FDA Regulations for selling EMpowerplus in Canada during the period of
January 1, 2003 and December 31, 2003. For the purposes of that prosecution, a
warrant application was made for a search of TrueHope’s business premises in
Raymond Alberta which was conducted in July 2003. The Applicants argue that,
because the action taken with respect to the April and May 2003 shipments are
mentioned in that warrant application, it is conclusive that the April seizure was
conducted for the purpose of that criminal law investigation.
[124]
As quoted
in Section I of these reasons, the fax from Mr. Neske to Mr. Stephan
immediately following the April seizure provides a statement of the reasons for
the seizure:
Re: E.M. Power +
Further to the shipment of 72
bottles of the above named product presently being detained, this shipment will
not be released at this time. The product is currently under investigation
for importation prohibited under the Food and Drugs Act Regulation A.01.040.
We hope to conclude this investigation quickly with your cooperation.
[Emphasis added]
(Applicants’ Record, Vol. 3,
p. 1034)
As mentioned above, Regulation A.01.040
reads as follows:
Subject to section A.01.044,
no person shall import into Canada for sale a food or drug the sale of which in
Canada would constitute a
violation of the Act or these Regulations.
[125]
Mr.
Neske’s letter makes it clear that the April seizure was with respect to the
importation into Canada of EMpowerplus and not the sale in Canada of EMpowerplus.
However, it is not clear as to whether the seizure was intended to be an administrative seizure and detention as
an immediate enforcement tool for controlling non-compliance or an evidentiary
seizure used to gather evidence for a prosecution. I find it was likely for both purposes.
[126] On the last
day of the hearing of the present Application, the April shipment was inspected
in open court and it was established that, subsequent to the seizure, some of
the seized product was extracted and sent for analysis. Therefore, I find that
this fact establishes that, in part, the seizure was used to gather evidence
for a prosecution for either unlawful sale or unlawful importation.
[127] As addressed
by Justice Lebel in Quebec v. Laroche, an important feature of a Section
8 analysis is a determination of whether the detention of property amounts to a
seizure for Charter purposes. In order for the Charter to be
engaged, a detention must have a superadded impact on privacy rights.
[128] In my
opinion, the following factors establish that Mr. Hardy and Truehope have no
credible basis upon which to make a Charter complaint about the seizure:
in the two years preceding the seizure there was a high degree of personal
contact between Mr. Hardy and officials of Health
Canada; during this period, Mr. Hardy knew
that TrueHope and Synergy were acting in violation of the FDA and the FDA
Regulations; Health Canada was patient in making it clear that the
violations could not be disregarded and compliance with the law was required;
and, most importantly, Mr. Hardy flatly refused to devise a way to put Synergy
and Truehope into compliance. Thus, when all factors are considered, I find
that Mr. Hardy and Truehope has no privacy right in the product seized, and, as
a result, the seizure had no superadded impact on either of them.
[129] Even if some
negligible privacy interest can be found in favour of Mr. Hardy and Truehope
which engages Section 8 rights, on the factors cited I find that the result is
the same. In this situation, it is agreed that, since the seizure of the April
shipment was conducted without a warrant, a rebuttable presumption arises that
the seizure is unreasonable; if a seizure is for an administrative purpose the
presumption is easy to rebut, while if the seizure is for a criminal law
purpose, the presumption is difficult to rebut (Hunter et al. v. Southam
Inc.,
[1984] 2 S.C.R. 145). Nevertheless, in my opinion, the presumption is rebutted
on the highest standard. I find that the seizure was very reasonable for both the
administrative and criminal law investigative purpose of stopping long standing
illegal conduct.
[130] As the final
point in the Section 8 analysis, Counsel for the Applicants argues that in C.E.
Jamieson, Justice Muldoon decided the predecessor to s. 23 was unconstitutional
and since it is agreed that there is no difference between it and s. 23,
therefore, s. 23 is unconstitutional. Paragraph 155 of the decision is argued
to have this effect:
Clearly, then, prior authorization was
feasible. Prior authorization would not have caused an imbalance in favour of
the plaintiff's expectation of privacy and security of property over the
State's valid objectives of law enforcement and safeguarding public safety.
Therefore, the warrantless seizure was unreasonable, and in contravention of
the [page670] Charter, section 8. To that extent, paragraph 22(1)(d) of the
Food and Drugs Act is declared to be, and to have been, of no force or effect.
[Emphasis
added]
[131] Counsel for
the Applicants argues that Justice Muldoon’s use of the phrase “of no force and
effect” supports a finding that s. 23 is unconstitutional. In my opinion, when
the phrase is read in context, this argument must be dismissed. The legal
finding in C.E. Jamieson is that the presumption that the seizure was
unreasonable was not rebutted, and, as a result, the search was found to
contravene the Charter. In my opinion, the comment that s. 22(1)(d) is declared
to be of “no force or effect” must be read only as a statement that the Charter
breach rendered the search to be of no force or effect.
[132] Support for
this conclusion is found in paragraph 156 of C.E. Jamieson where Justice
Muldoon says:
The seizure is quashed as
being unlawful. The seizure only is declared unconstitutional. […]
[Emphasis added]
In addition, at the end of the decision
under the heading “Summary of Conclusions” at paragraph 158, relief is granted
in the following terms:
... the seizure of articles
conducted on December 17, 1984, by the defendant Director, and the inspectors,
officials and any other public
servants who were then
members of his staff or otherwise authorized to effect such seizures, was
and is illegal, null and void, in particular, in that said seizure was
unreasonable and contravened section 8 of the Canadian Charter of Rights and
Freedoms.
[Emphasis added]
[133] Therefore, I
find that C.E. Jamieson does not stand for the proposition that
s. 23 is unconstitutional.
[134] In the end
result, I find that the April 2003 seizure does not offend Mr. Hardy’s or
Truehope’s Section 8 rights.
V. Conclusion
on the Present Application
[135] The Application
is dismissed.
ORDER
THIS COURT
ORDERS that:
1. The Application is dismissed.
2. The issue of costs is reserved
for determination following further argument.
“Douglas
R. Campbell”